

## CURRICULUM VITAE

**NAME:** Alan H. B. Wu, Ph.D., D.A.B.C.C., F.A.C.B.

**Position:** Chief, Clinical Chemistry and Toxicology Laboratories, San Francisco General Hospital  
Professor, Dept. Lab. Medicine, University of California at San Francisco  
Chief, Clinical Pharmacogenomics Laboratory, UCSF

**Address:** San Francisco General Hospital  
Clinical Chemistry Laboratory, Room 2M27  
1001 Potrero Ave.  
San Francisco, CA 94110

Business Phone: Voice: 415-206-3540  
FAX 415-206-3045  
email:wualan@labmed2.ucsf.edu

### EDUCATION:

1971-1975	Purdue University, W. Lafayette, IN	B.S. Honors, Chemistry, B.S., Biology.
1975-1980	University of Illinois, Urbana, IL	Ph.D. Analytical Chemistry.
1980-1982	Hartford Hospital, Hartford, CT	Post-Doctoral Fellow Clinical Chemistry and Toxicological Chemistry

### LICENSES, CERTIFICATION:

1984	American Board of Clinical Chemistry Certification: Clinical Chemistry
1985	American Board of Clinical Chemistry Certification: Toxicological Chemistry
2005	State of California, Certified as a Clinical Chemistry Laboratory Director

### EMPLOYMENT:

1982-1988	Asst. Prof., Dept. Pathology & Lab Medicine, Univ. Texas, Houston
1982-1984	Assoc Director Clinical Chemistry & Toxicology Hermann Hospital, Houston TX
1982-1992	Assoc. Prof., Dept. Pathology & Lab Medicine, Univ. Texas, Houston
1984-1992	Director, Clinical Chemistry & Toxicology, Hermann Hospital, Houston TX
1982-1994	Faculty, Graduate School of Biomedical Science, Univ. Texas, Houston
1990-1992	Section Chief, Clin Chem Lab, L.B. Johnson General Hospital, Houston
1990-1992	SAMHSA-Certified Toxicology Laboratory Director, Hermann Hospital, Houston
1992-2004	Director, Clin Chem & Toxicology Laboratories, Hartford Hospital, Hartford CT
1993-2004	Associate Professor, Dept. Chemistry, Univ. Connecticut, Storrs
1993-2004	Associate Prof., Dept. Pathobiology, Univ. Connecticut, Storrs
1993-1997	Assoc. Prof., Dept. Laboratory Medicine, Univ. Connecticut, Farmington
1995-2002	SAMHSA-Certified Toxicology Laboratory Director, Clinical Lab Partners, Newington CT

1997-2004 Professor, Dept. Laboratory Medicine, Univ. Connecticut, Farmington  
 1998-2004 Director, Clinical Path, Dept Pathology & Lab Medicine, Hartford Hospital  
 2004-present Division Chief, Clinical Chemistry, Dept. Lab Medicine, S.F. General Hospital  
 2004-present Professor, Dept. Lab Medicine, Univ. of California at San Francisco  
 2008-present Adjunct Professor, Professional Science Master's Program in Biotechnology, San Francisco State University  
 2011-present Adjunct Professor, Dept. of Clinical Pharmacy, Univ. of California, San Francisco  
 2013-present Laboratory Director, Dept. Public Health Newborn Screening Program, Richmond CA

**OTHER POSITIONS HELD CONCURRENTLY:**

2004-present California Poison Control Center Medical Advisory Committee  
 2005-present Program Director, COMACC-accredited Clinical Chemistry Postdoctoral Program, University of California, San Francisco  
 2006-present College of American Pathologists, Toxicology Resource Committee  
 2006-present College of American Pathologists, Pharmacogenomics Resource Subcommittee  
 2008-present National Academy of Clinical Biochemistry Nominating Committee

**HONORS AND AWARDS:**

2010 Visiting Professor, Wenzhou Medical College, Wenzhou, China  
 2011 Nominated, Charles C. Shepard Science Award, Laboratory and Methods, CDC/ATSDR  
 2011 Honorary consultant, Kaoshiung General Veterans Hospital  
 2012 Simon Dack Award for Outstanding Scholarship, Journal of the American College of Cardiology.  
 2013 Honorary Professor, TEDA International Cardiovascular Hospital, Tianjin Medical University.  
 2013 American Association for Clinical Chemistry Outstand Speaker Award  
 2014 Harold Van Remortel Service Award for Service to the Northern California Section of the American Association for Clinical Chemistry  
 2014 Albert L. Nichols Innovation Award in Laboratory Medicine from the Southern California Section of the American Association for Clinical Chemistry  
 2015 Ching-Nan Ou Lecture in Clinical Chemistry, Texas Children's Hospital  
 2015 National Academy of Clinical Biochemistry Distinguished Abstract Award  
 2017 Canadian Society for Clinical Chemistry Traveling Lecture Award  
 2018 American Association for Clinical Chemistry Society for Young Clinical Laboratorians, Mentor Award.  
 2018 Norman P. Kubasik Lectureship Award, Update New York AACC Section

**CLINICAL ACTIVITIES**

Director, Clinical Chemistry and Toxicology at San Francisco General Hospital. I supervise all of the professional activities in these laboratories including supervision of all personnel,

development and approval of all new laboratory tests and instruments, compliance with regulatory agencies, sign-out reports, and all communications with the house staff and medical staff.

**OTHER PROFESSIONAL ACTIVITIES:**

**MEMBERSHIP in PROFESSIONAL SOCIETIES**

American Association for Clinical Chemistry

Northern California Section American Association for Clinical Chemistry

**RECENT INVITED PRESENTATIONS**

**INTERNATIONAL**

Charitie Hospital, Grand Rounds, Berlin, Germany, 2003-2006.

Chinese Clinical Chemistry and Laboratory Medicine Congress, Nanjing, China, 2004

The Bergmeyer Conference, Munich, Germany, 2005.

International Heart Forum, Beijing, China, 2005 and 2006.

Society of Chinese Bioscientists in America, San Francisco, CA 2006

Spanish Society of Clinical Chemistry and Molecular Pathology, Bilbao, Spain, 2006

Annual Conference of Chinese Association of Clinical Biochemistry, Taipei, Taiwan, 2007.

2<sup>nd</sup> International Symposium Integrated Biomarkers in Cardiovascular Disease, Berlin, 2007

South Pacific Congress of Pathology and Laboratory Medicine, Auckland, 2007.

Asian-Pacific Congress of Clinical Biochemistry, Beijing, 2007

Shandong International Laboratory Medicine Conference, Shandong, China 2009

Asian Pacific Conference of Chromatography and Mass Spectrometry, Hong Kong, 2010

Hong Kong Sanatorium & Hospital, Hong Kong, China, 2009

International Society of Enzymology, Crete, Greece, 2010

Wenzhou Medical College, Wenzhou, China, 2010

Asian Pacific Conference of Clinical Chemistry and Laboratory Medicine, Seoul, Korea, 2010

Brazilian Congress of Clinical Analysis, Curitiba, Brazil, 2011.

Chinese Laboratory Medicine Congress, Taipei, Taiwan, 2011.

National Cheng Kung University, Tainan, Taiwan, 2011.

4<sup>th</sup> World Chinese Mass Spectrometry Conference, Tainan, Taiwan, 2012

Chia Nan University, Tainan, Taiwan, 2012

Chinese Academy of Clinical Biochemistry, Taipei, Taiwan, 2012.

Kaohsiung Veterans General Hospital, Kaohsiung, Taiwan, 2011.

Tianjin Biomedical Engineering Society of Cardiovascular Critical Care Medicinal, Tianjin, China, 2013

5<sup>th</sup> Abbott Asia Pacific Scientific Symposium, Shanghai, China 2012.

The Science of Caring, Abbott Laboratories, Ho Chi Minh City, Viet Nam, 2014.

Korean Society of Laboratory Medicine, Seoul, 2014.

Vancouver Pharmaceutical & BioScience Society, Vancouver, Canada, 2014

Chinese Society of Laboratory Medicine, Chongqing, PROC, 2016

I.M. Sechenov First Moscow State Medical University, 2016

Wuhan Cardiovascular Hospital, Wuhan, PROC, 2016

Italian Society of Laboratory Medicine, Turin, 2016  
Canadian Society of Clinical Chemistry, Visiting Lectureship, Calgary, Winnipeg, Toronto,  
Montreal, Halifax, 2017  
Korean Society of Laboratory Medicine Conference, Seoul, 2018

#### NATIONAL

University of California San Diego Biomarkers in CV Disease Symposium, 2006-2016  
Am. Association for Clinical Chemistry, Annual Meeting, Workshops and Symposia 2004-2009  
University of Texas Southwestern Medical School Grand Rounds, Dallas, TX 2006, 2007.  
College of Veterinary Internal Medicine Annual Meeting, San Antonio, 2008  
Integrated Biomarkers in Cardiovascular Disease, Seattle, WA 2008  
Association of Molecular Pathologists, Workshops, Los Angeles 2007, Grapevine TX, 2008,  
2011.  
Association of Clinical Scientists, Symposium, Los Angeles, 2008  
Clinical Ligand Assay Society Annual Meeting, Coral Springs, FL, 2008  
Methodist Hospital Grand Rounds, Houston, TX 2008  
University of California San Diego Grand Rounds, San Diego, CA 2008  
M.D. Anderson Hospital Grand Rounds, Houston, TX 2009  
University of California, San Diego Mass Spectrometry Applications to Clinical Practice, 2008.  
University of Minnesota, Grand Rounds, Minneapolis, MN 2009  
Transcatheter Cardiovascular Therapeutics Annual Meeting, San Francisco, CA 2009  
University of Minnesota Lab Medicine and Pathology Grand Rounds, Minneapolis, MN 2009  
Bioconference Live. Pharmacogenomics 2010, high sensitivity troponin 2013.  
Personalized Medicine World Congress, Mountain View, CA 2010  
American Association for Clinical Chemistry Profession Practice Review Course, 2013  
American College of Cardiology Annual Meeting, San Francisco CA 2013  
University of California, Los Angeles Grand Rounds, Los Angeles, CA 2013  
Personalized Medicine World Conference, Mountain View, CA, 2014  
Academy of Clinical Laboratory Physicians and Scientists, San Francisco, CA 2014  
New York Metro, AACC Section Meeting, New York City, NY 2015  
Pacific Northwest AACC Section, Portland, NY 2015  
MD Anderson Cancer Center Grand Rounds, Houston, TX 2015  
Univ. Texas San Antonio Grand Rounds, San Antonio, TX 2015  
Hermann Hospital Lecture in Clinical Chemistry, Houston, TX 2015  
Baylor College of Medicine, Grand Rounds, Houston, TX 2015  
Massachusetts General Hospital Grand Rounds, Boston, MA 2015  
Wake Forest Baptist University Medical Center, Winston-Salem, NC 2016  
Winston-Salem State University, NC 2016  
American Heart Association Annual Meeting, New Orleans, LA 2016  
National Institute of Health Clinical Chemistry Lab, Bethesda, MD 2017  
Food and Drug Administration, CDER, Silver Springs, MD 2017  
Temple University Grand Rounds, Philadelphia, PA 2018

University of Pennsylvania Grand Rounds, Philadelphia, PA 2018  
Hershey Medical Center Grand Rounds, Hershey, PA 2018  
American Academy of Forensic Science, Annual Meeting, Seattle WA 2018  
Stanford University Grand Rounds, Palo Alto, CA 2018  
Upstate New York Local AACC Section Meeting, 2018  
Grand Rounds, Dartmouth Hitchcock Medical Center, 2019

## **REGIONAL**

John Muir Medical Center, Walnut Creek, CA, 2009.  
Selected Topic in Intensive Respiratory Care, SFGH, San Francisco, CA 2009  
SFGH Dean's Lecture, 2009.  
Asian Heart and Vascular Symposium, 2010  
Sg2 INSIGHT, UCSF, 2010  
UCSF Cardiovascular Symposium, 2010  
Chinese American Biopharmaceutical Society, Foster City, CA 2012  
UCSF Division of Cardiology, San Francisco, CA 2014  
California Society of Pathologists, San Francisco, CA 2014  
Northern California AACC Local Section, 2015  
Univ. of California, Davis Grand Rounds, Sacramento, CA 2015  
California Association for Medical Laboratory Technology, Sacramento CA 2015  
Cedar Sinai Medical Center, Los Angeles, CA 2016  
University of Southern California, Los Angeles, CA 2016  
University of California San Francisco Precision Medicine Conference, San Francisco, CA 2016  
Dominican Hospital, San Cruz, 2016  
University of California San Francisco 2<sup>nd</sup> Precision Medicine Conference, 2016  
University of California San Francisco 5<sup>th</sup> Asian Health Symposium, 2016  
Northern California American Association for Clinical Chemistry, 2015, 2016  
UCSF Explore Symposium, 2018

## **LECTURES TO LAY PUBLIC**

UCSF Osher Mini Medical School for the Public  
The Forum Retirement Home, Cupertino, CA  
Oshman Family Jewish Community Center, Palo Alto CA  
Orinda Rotary Club, Orinda, CA  
Galileo High School, San Francisco, CA  
Lowell High School, San Francisco, CA  
Nerd Night, Los Angeles, CA  
Commonwealth Club, San Francisco, CA  
Military Officers Association of America, Santa Clara, CA  
Nerd Night, San Jose, CA

## **TEACHING & MENTORING**

CLINICAL TEACHING – Department of Laboratory Medicine Residents.

AMERICAN CHEMICAL SOCIETY PROJECT SEED SUMMER FELLOWSHIPS

2005 Alicia Wong, High School Senior  
2006 Dana Le, HS Senior  
2007 Vanessa Munoz, HS Junior  
2008 Vanessa Munoz, HS Senior  
2008 Liza Chu, HS Junior  
2008 Laura Ruan, HS Junior  
2010 Jessie Huang, HS Junior

GRADUATE STUDENTS, DEPARTMENT OF PHARMACEUTICAL SCIENCE AND PHARMACOGENOMICS

2006 Simone Tchu, UCSF, Graduate Thesis Committee Chair  
2006 Howard Horng, UCSF, Graduate Thesis Committee  
2007 Katherine Drake, UCSF, Graduate Student Laboratory Rotation  
2008 Lisa Singer, UC Berkeley MD/PhD Medical Science Training Program  
2012 Xiaomin Liang, UCSF Graduate Student laboratory Rotation  
2014 Rosa Chan, UCSF Graduate Student Thesis Committee

VISITING GRADUATE STUDENTS

2010 Andrea Pinkowski, Charitie Hospital, Berlin  
2010 Hanna Herman, Charitie Hopsital, Berlin  
2010 Kilian Casgrande, Clermont-Ferrand University, France  
2010 Anthony Rahon, Clermont-Ferrand University, France  
2010 Toni Lauderbach, Charitie Hospital, Berlin  
2010 Tab Toochinda, University of Pittsburgh  
2013 Wei Lun Tsai, National Cheung Kung University Hospital, Tainan, Taiwan  
2013 Bei-Tzu Wang, National Cheung Kung University, Tainan, Taiwan  
2016 Zineb Aoullay, Mohamed V Souissi University, Morocco2017

POSTDOCTORAL FELLOWS PERSONALLY SUPERVISED:

2004-2006 Ping Wang, Ph.D., University of Wisconsin  
2006-2007 Joern Vollert, M.D, Charitie Hospital, Berlin  
2006-2008 Julia Drees, Ph.D., University of Wisconsin  
2007-2008 Stephan Hergert, M.D., Charitie Hospital, Berlin  
2007-2009 Kara Lynch, Ph.D., University of Wisconsin  
2008 HanPing Wang, M.D., Guangzhou Medical College, People's Republic of China  
2008-2010 Deborah French, Ph.D., University of Strathclyde, Glasgow, UK  
2008-2009 ChuanXin Wang, MD, PH.D., Qilu Hopsital of Shandong University  
2009-2011 Roy Gerona, Ph.D., University of Wisconsin  
2009-2010 Leiguang Hu, Ph.D., Shanghai Jingan Hospital

2010-2012 Matt Petrie, Ph.D., University of Wisconsin  
 2011-present Moudi Assisi, Kuwait University  
 2011-2013 Sarah Shugarts, Ph.D., University of California, San Francisco  
 2011-2012 Yeongsic Kim, MD, Ph.D., Catholic University Medical College, Seoul Korea  
 2011-2013 Katie Thoren, Ph.D., University of California, Berkeley  
 2012-2014 Jennifer Colby, Ph.D., University of California, Berkeley  
 2013-2016 He Sarina Yang, Ph.D., Northwestern University  
 2014-2017 Howard Horng, Ph.D., University of California, San Francisco  
 2015-2017 Xander Van Wijk, Ph.D., University of California, San Diego  
 2016-2017 Fatameh Fouladkou, Ph.D., University of Toronto  
 2017-2018 Yeung Ok Lee, M.D., Catholic University Medical College, Seoul Korea  
 2017-2018 Yanhui Ma, M.D., Ph.D., Shanghai JiaoTong University School of Medicine  
 2017-present Ruben Luo, Ph.D., Stanford University  
 2018-present Adina Badea, Ph.D., University of Illinois  
 2018-present Jeffrey Witman, M.D., University of California, San Francisco  
 2018-present Yu Zhang, MD, Ph.D., Tsinghua University, China

#### TEACHING AWARDS

1983,84,87,88,89 Dean's Teaching Excellence List, University of Texas Medical School  
 1994,2000 Dept. Pathology, Hartford Hospital, Resident Teaching Award.  
 2018 School of Pharmacy Apple Teaching Award

#### CONTINUING EDUCATION

2008 Scientific Symposium International, Advances in Laboratory Medicine  
 2009 Am. Assoc. for Clin Chem Audioconference: "Managing Low Level Troponin Elevations."

#### SUMMARY OF TEACHING DUTIES:

2008-2009 Clinical teaching (pathology residents): 250 hours  
 Laboratory teaching (postdoctoral fellows): 50 hours  
 Graduate student teaching (UCSF PSPG and UC Berkeley): 50 hours  
 Medical technology instruction: 25 hours  
 Instructor, Advances in Laboratory Medicine, Clinical Chemistry,  
 Toxicology and Microbiology, 5 hours

#### EDUCATIONAL COMPUTER SOFTWARE:

1. Wu AHB, Jenkins B, Fath SJ, LaRocco M, Bracey A, Simon FA. Computer assisted learning for clinical pathology. Health Sciences Consortium, Chapel Hill, NC:1989. (13 cases, and 19 sessions).
2. Wu AHB. Clinical chemistry quiz. AACC Press, Washington DC:1990.
3. Wu AHB. Urinalysis tutorial. Warlock Productions, Hanover, NH:1991.
4. Wu AHB. The chemistry profile. Warlock Productions, Hanover, NH:1993.

5. Wu AHB, Wu PL. Methods in clinical chemistry. Warlock Productions, Hanover, NH:1994.
6. Electrophoresis. Warlock Productions, Hanover, NH: 2001.

## **SERVICE**

### **DEPARTMENTAL SERVICE**

- 2006-2007 Dept. Laboratory Medicine Search Committee SFGH Laboratory Director  
 2007 Dept. Laboratory Medicine Search Committee SFGH Hematology Director  
 2007-present Dept. Laboratory Medicine Academic Personnel Manual Committee  
 2008-present SFGH Laboratory-Therapeutics Subcommittee

### **UNIVERSITY SERVICE**

- 2005-present Dept. Pharmaceutical Science and Pharmacogenomics Graduate Admission Committee  
 2007 Dept. Pharmacy, Faculty Search Committee  
 2013-present Integration of Pharmacogenetics into Apex working committee  
 2014 USCF Stewardship Review Committee  
 2018-present UC Berkeley Biomedical Engineering Advisory committee

### **SFGH HOSPITAL SERVICE**

- 2005-present Advisory Committee to the General Clinical Research Center, SFGH

## **GOVERNMENT SERVICE**

- 2002-2004 State of CT, Environmental Biomonitoring Committee  
 2002-present State of CT, Terrorism Preparedness Committee  
 2004-present California Poison Control Center Medical Advisory Committee  
 2006-present NIH Small Business Grant Review Committee (SBIR), Cardiovascular Sciences  
 2008 NHLBI Interagency Grant Review Committee  
 2008-present UC Davis-Lawrence Livermore National Laboratory Point-of-Care Technologies Center Grant Review Committee  
 2010-2012 UCSF CTSI Research Allocation Program Grants. Grant Review Committee.  
 2012-2013 Consultant, Agency for Healthcare Research and Quality

## **STUDY GROUPS**

- 2007-present PharmGKB, Stanford University, International Warfarin Pharmacogenetics Consortium  
 2009-present PharmGKB, Stanford University, International Tamoxifen Pharmacogenetics Consortium  
 2008-present NHLBI Coagulation Trial, Central Lab and Genotyping Committee

## **SERVICE TO PROFESSIONAL SOCIETIES**

- 1985-2003 Commission on Accreditation in Clinical Chemistry, President.  
 1990-1996 American Board of Clinical Chemistry, member, Vice President.



1994-2004 Hartford County Medical Assoc., Committee on Physician Health, Medical Advisory Board Member

2000-2004 Connecticut Committee on Physician Health, Consultant

2000-2002 Massachusetts Committee on Physician Health, Consultant

2000-2002 New York Committee on Physician Health, Consultant

1996-present Am Assoc Clin Chem. Troponin Standardization Committee, Member.

1997-present Int. Fed. Clin Chem, Standardisation of Markers of Cardiac Damage, Member.

2005-2009 Am Assoc Clin Chem. Evidence Based Medicine Committee

2006-present College of American Pathologists, Toxicology Resource Committee

2007-present Society of Chest Pain Accreditation Review Committee

2008-present Nominating Committee, AACC Molecular Diagnostics Division

2009-present Advisor, Clinical Laboratory Standards Institute, Subcommittee on Establishing Molecular Methods in Clinical Laboratory Environments

2015-present Northern California Section AACC Program Chair

#### **SERVICE TO PROFESSIONAL PUBLICATIONS:**

1993-1999 Editor, "Clinical Chemistry Questions and Answers," *JIFCC*.

1996-present Editorial Board, *Annals of Clinical and Laboratory Science*.

1998 Editorial Board, *Clinical Chemistry*.

1998-present Editor-in-Chief, *Clinica Chimica Acta*.

1998-2016 Book Series Editor, *Pathology and Laboratory Medicine*, Humana Press.

2001-present Editorial Board, *Journal of Point-of-Care Testing and Near Patient Technology*

Present Journal reviewer: *Clin Chem*, *Clin Biochem*, *Circulation*, *J Am Col Cardiol*, *Am Heart J*, *Eur Heart J*, *Eur J Heart Fail*, *Crit Care Med*, *Pharmacol Ther.*, *Ann Int Med*, and others (6-8 per month).

2008-present Editorial Board, *Personalized Medicine*.

2008-present Reviewer for Evidence Report/Technology Assessment. DHHS, Agency for Healthcare Research and Quality (AHRQ).

2011-present. Editorial Board, *Journal of the American College of Cardiology*

2012-present Editorial Board, *Journal of Clinical Pharmacology and Therapeutics*

2015-present Editorial Board, *Practical Clinical Chemistry*

2015-present Editorial Board, *Journal of Applied Laboratory Medicine*

2017-present Editor-in-Chief, *Frontiers in Laboratory Medicine*

#### **PEER REVIEWED PUBLICATIONS:**

1. Wu AHB, Malmstadt HV. A versatile microcomputer-controlled titrator. *Anal Chem* 1978;50:1090-6.
2. Wu AHB, Rotunno T, Malmstadt HV. The determination of protein nitrogen in feed and wheat using a microcomputer-controlled titrator. *J Assoc Off Anal Chem* 1978;62:969-75.
3. Wu AHB, Malmstadt HV. Reactions during the titration of ammonia with hypochlorite in the presence of bromide. *Anal Chem* 1981;53:1725-6.

4. Wu AHB, Bowers GN Jr. Evaluation and comparison of immunoinhibition and immunoprecipitation methods for differentiating MB from BB and macro forms of creatine kinase isoenzymes in patients and healthy individuals. *Clin Chem* 1982;28:2017-21.
5. Wu AHB, Stout R, McComb RB. Falsely high creatinine concentration associated with severe methanol intoxication. *Clin Chem* 1983;29:205-8.
6. Wu AHB, Herson VC, Bowers GN Jr. Macro creatine kinase type 1 and 2: Clinical significance in neonates and children as compared with adults. *Clin Chem* 1983;29:201-4.
7. Wu AHB, Parker OS, Ford L. Hyperviscosity and hyaluronic acid in serum in a case of Wilms' tumor. *Clin Chem* 1984;30:914-6.
8. Wu AHB, Strocchia C, Gornet TG, Edwards J. An inexpensive lyophilized control for cardiac isoenzymes. *Clin Chem* 1984;30:1718.
9. Wu AHB, Gornet TG. Preparation of urine samples for liquid chromatographic determination of catecholamines: bonded - phase phenylboronic acid, cation-exchange resin and alumina adsorbents compared. *Clin Chem* 1985;31:298-302.
10. Wu AHB, Gornet TG, Bretaudiere JP, Panfili PR. Comparison of enzyme immunoassay and immunoinhibition for creatine kinase MB in diagnosis of acute myocardial infarction. *Clin Chem* 1985;31:470-4.
11. Wu AHB, Gornet TG. Measurement of creatine kinase MM sub-type by anion-exchange liquid chromatography. *Clin Chem* 1985;31:1841-5.
12. Spain MA, Wu AHB. Bilirubin interference with determination of uric acid, cholesterol, and triglycerides in peroxidase-coupled systems and the effect of ferrocyanide. *Clin Chem* 1986;32:518-21.
13. Wong SS, Wu AHB. Thrombolytic therapy for acute myocardial infarction. *AACC Ther Drug Monit-Toxicol Update* 1986;8(2):1-4.
14. Wu AHB, Wong SS, Brockie R, Nishikawa, A. Comparison of three cases of acute myocardial infarction treated with thrombolytic therapy. *AACC Ther Drug Monit-Toxicol Update* 1986;8(3):1-4.
15. Bracey A, Wu AHB, Aceves J, Chow T, Carlile S, Hoots WK. Platelet dysfunction associated with Wilms' tumor and hyaluronic acid. *Am J Hematol* 1987;24:247-57.
16. Wu AHB, Bracey A, Bryan-Brown CW, Harper JV, Burritt MF. Ionized calcium monitoring during liver transplantation. *Arch Path Lab Med* 1987;111:935-8.
17. LeMaistre A, Bracey A, Katz A, Wu AHB. The role for qualitative hCG assays in the diagnosis of ectopic pregnancy. *Clin Chem* 1987;33:1908-10.
18. Wong SS, Wu AHB, Fritsche HA. Re-evaluation of creatine kinase BB as a tumor marker. *Clin Chem* 1987;33:809-11.
19. Wu AHB, Gornet TG, Wu VH, Brockie R, Nishikawa A. Early diagnosis of acute myocardial infarction by rapid analysis of creatine kinase isoenzyme-3 (CK-MM) sub-types. *Clin Chem* 1987;33:359-62.
20. Wong SS, Earl R, Wu AHB. Simultaneous presence of IgA- and IgG-CK-BB in a patient without myocardial infarction. *Clin Chim Acta* 1987;166:99-100.

21. Wu AHB, Wong SS, Waldron C, Chan DW. Automated quantitative measurement of human chorionic gonadotropin: analytical correlation between serum and urine with creatinine correction. *Clin Chem* 1987;33:1424-6.
22. Jone CM, Wu AHB. An unusual case of toluene-induced metabolic acidosis. *Clin Chem* 1988;34:2596-9.
23. Wu AHB. Creatine kinase isoforms in ischemic heart disease. *Clin Chem* 1989;35:7-13.
24. Reed RL, Wu AH, Miller-Crotchett P, Crotchett J, Fischer RP. Pharmacokinetic monitoring of nephrotoxic antibiotics in surgical intensive care patients. *J Trauma* 1989;29:1462-70.
25. Wu AHB, Gornet TG, Harker CC, Chen HL. Role of rapid immunoassays for urgent ("stat") determination of creatine kinase MB. *Clin Chem* 1989;35:1752-6.
26. Peaceman AM, Wu AHB. The use of magnesium sulfate in pregnancy. *AACC Ther Drug Monit-Toxicol Update* 1989;10(8):1-4.
27. Wu AHB, Schwartz JG. Update on creatine kinase isoenzyme assays. *Diag Clin Test* 1989;27(8):16-20.
28. Wu AHB, LaRocco M, Fath SJ, Simon FA. Evaluation of computer case simulations for teaching clinical pathology to second-year medical students. *Ann Clin Lab Sci* 1990;20:152-8.
29. Jone CM, Wu AHB, Spillman T, Fritsche HA. Screening antisera for subtype specificity based on immunoblotting of lectin affinity electrophoresis: application towards alpha fetoprotein subfractions. *J Clin Lab Anal* 1990;4:307-12.
30. Rosano T, Ambrose RT, Wu AHB, Swift TA, Yadegari P. A candidate reference method for serum creatinine: method development and inter-laboratory validation. *Clin Chem* 1990;36:1951-5.
31. Khalil SN, Florence FB, Van den Niewenhuyzen MCO, Wu AHB, Stanley TH. Rectal methohexital: concentration and length of the rectal catheters. *Anest Anag* 1990;70:645-9.
32. Onigbinde TA, Wu AHB, Johnson M, Wu YS, Collinsworth WL, Simmons MJ. Clinical evaluation of an automated chemical inhibition assay for lactate dehydrogenase (LD)-1 isoenzyme. *Clin Chem* 1990;36:1819-22.
33. Gauthier J, Smalling RW, Wu AHB, Buja LM. A clinicopathologic conference: severe anginal pain in a 58-year old man. *Houston Med* 1991;7:58-69.
34. Wu AHB. Pharmacokinetic aspects of ethanol for medico-legal purposes. *AACC Ther Drug Monit-Toxicol Update* 1991;12(12):5-18.
35. Onigbinde TA, Wu AHB. Full-scan gas chromatography-mass spectrometry analysis for drug testing in urine using an ion trap. *AACC Ther Drug Monit-Toxicol Update* 1992;13(7):9-23.
36. Wu AHB. Creatine kinase MM and MB isoforms. *Lab Med* 1992;23(5):303-5.
37. Reed RL, Ericsson CD, Wu A, Miller-Crotchett P, Fischer RP. Pharmacokinetics of prophylactic antibiotics. *J Trauma* 1992;32:21-7.
38. Wu AHB, Johnson KG, Onigbinde TA, Wong SS. Evaluation of full-scanning GC/ion trap MS analysis of drugs of NIDA drugs-of-abuse in urine. *J Anal Toxicol* 1992;16:202-6.

39. Wu AHB, Onigbinde TA, Johnson KG, Wong SS. Identification of methamphetamines and over-the-counter sympathomimetic amines by full-scan GC/Ion trap MS with electron impact and chemical ionizations. *J Anal Toxicol* 1992;16:137-41.
40. Wu AHB, Onigbinde TA, Johnson KG, Wimbish GH. Alcohol-specific cocaine metabolites in serum and urine of hospitalized patients. *J Anal Toxicol* 1992;16:132-6.
41. Wu AHB, Wong SS, Johnson KG, Ballatore A, Seifert WE. The conversion of ephedrine to methamphetamine and methamphetamine-like compounds prior to GC/MS analysis of CB and HBFA derivatives. *Biol Mass Spectrom* 1992;21:278-84.
42. Wu AHB. Therapeutic drug monitoring for the 1990s: meeting the laboratory needs of a changing environment. *Wiener Klin Wochen* 1992;191, Suppl., 19-22.
43. Jarausich J, Collinsworth W, Cano Y, Hafner G, Hammer E, Malandain H, Pokieser L, Redondo FL, Schlebusch H, Taylor A, Thomsen L, Weindel K, Wieland H, Willems D, Windisch M, Woods M, Wu AHB, Zebelmann A. Results of the multicenter evaluation of a novel homogeneous immunoassay for digoxin based on the cloned enzyme donor immunoassay technology. *Wiener Klin Wochen* 1992;191, Suppl., 69-72.
44. Klein G, Collinsworth W, Courbe A, Diez O, Domke I, Hanseler E, Haux P, Kattermann R, Knoke A, Lehmann P, Moia F, Nelson P, Ollerich M, Suigo E, Torralba A, Valdes R Jr, Wilders-Truschnig M, Wu AHB. Results of the multicenter evaluation of the CEDIA phenobarbital assay. *Wiener Klin Wochen* 1992;191, Suppl., 43-47.
45. Klein G, Collinsworth W, Courbe A, Fuentes-Arderiu X, Graham J, Hanseler E, Hannak D, Kattermann R, Knoke A, Lehmann P, Mastropaolo W, Moia F, Nelson P, Oellerich M, Suigo E, Torralba A, Wilders-Truschnig M, Wu AHB. Results of the multicenter evaluation of the CEDIA phenytoin assay. *Wiener Klin Wochen* 1992;191, Suppl., 38-42.
46. Klein G, Castineiras MJ, Collinsworth W, Courbe A, Delavenne M, Hanseler E, Hannak D, Kaspar P, Kattermann R, Knoke A, Mastropaolo W, Moia F, Nelson P, Oellerich M, Suigo E, Swanson R, Torralba A, Valdes R Jr, Wilders-Truschnig M, Wu AHB. Results of the multicenter evaluation of the CEDIA theophylline assay. *Wiener Klin Wochen* 1992;191, Suppl., 31-37.
47. Tso G, Wu AHB, Wong SS. Screening for drugs-of-abuse by Syva II reagents. *Res Comm Sub Abuse* 1992;13,256-68.
48. Wu AHB, Johnson KG, Wong SS. Impact of revised HHS guidelines for methamphetamine testing in urine. *Clin Chem* 1992;38:2352-3.
49. Onigbinde TA, Wu AHB, Wu YS, Simmons MJ. Mechanism of differential inhibition of lactate dehydrogenase isoenzymes in the BMD LD-1 assay. *Clin Biochem* 1992;25:425-9.
50. Wu AHB, Wang X-M, Gornet TG, Ordonez-Llanos J. Creatine kinase MB isoforms in patients with myocardial infarction and skeletal muscle injury. *Clin Chem* 1992;38:2396-400.
51. Wu AHB, Perryman MB. Clinical applications of muscle enzymes and proteins. *Curr Opin Rheumatol* 1992;4:815-20.

52. Wu AHB, Gornet TG, Schenkel O, Smith-Cronin L, Graham GA, Tonnesen AS, BA McKinley. Preliminary evaluation of an experimental clinical chemistry analyzer developed for space medicine. *Clin Chem* 1993;39:22-36.
53. Wu AHB, Taylor GR, Graham GA, McKinley BA. The clinical chemistry and immunology of long-duration space missions. *Clin Chem* 1993;39:37-44.
54. Friedman DL, Wu AHB, Gornet TG, Kesterson R, Chen L, Puleo P, Perryman MB. Recombinant creatine kinase proteins and proposed standards for creatine kinase isoenzyme and subform assays. *Clin Chem* 1993;39:1598-601.
55. Wu AHB, Wong SS, Johnson KG, Callies J, Shu DX. Evaluation of the Triage system for emergency testing of phencyclidine, amphetamines, opiates, and tetrahydrocannabinol in serum. *J Anal Toxicol* 1993;17:241-5.
56. Caprioli R, Wu AHB. Mass spectrometry. In *Review of Clinical Chemistry*. *Anal Chem* 1993;65:R470-4.
57. Wu AHB, Liu N, Cho YJ, Johnson KG, Wong SS. Extraction and simultaneous elution and derivatization of tetrahydrocannabinol using Toxi-Lab SPEC prior to GC/MS analysis of urine. *J Anal Toxicol* 1993;17:215-7.
58. Abouleish E, Rawal N, Tobon-Randal B, Rivera-Weiss M, Meyer B, Wu A, Rashad MN. A clinical and laboratory study to compare the addition of 0.2 mg of epinephrine, or their combination to hyperbaric bupivacaine for spinal anesthesia in Casarean section. *Anesth Analg* 1993;77:457-62.
59. O'Connor E, Ostheimer D, Wu AHB. Limitations of forensic urine drug testing by methodology and adulteration. *AACC Ther Drug Monit-Toxicol Update* 1993;14:275-96.
60. Green S, Wu AHB. Immunoassays and electrophoresis for creatine kinase isoenzymes and isoforms in diagnosis and management of acute myocardial infarction. *AACC Endo* 1993;11:329-44.
61. Wong SS, Liu N, Wu AHB. An improved quantitative APT test for the detection of fetal hemoglobin in blood stools of the newborn. *Clin Chem* 1993;39:2326-9.
62. Wu AHB, Ostheimer D, Cremese M, Forte E, Hill D. Characterization of drug interferences caused by coelution of substances in GC/MS confirmation of targeted drugs in full scan and SIM modes. *Clin Chem* 1994;40:216-20.
63. Wu AHB. Cardiac troponin T: biochemical, analytical, and clinical aspects. *J Clin Immunoassay* 1994;17:45-8.
64. Wu AHB, Laios I, Green S, Gornet TG, Wong SS, Parmaley L, Tonnesen A, Plaisier B, Orlando R. Immunoassays for serum and urine myoglobin: myoglobin clearance assessed as a risk factor for acute renal failure. *Clin Chem* 1994;40:796-802.
65. Wu AHB, Valdes R Jr, Apple FS, Gornet T, Stone MA, Mayfield-Stokes S, Ingersoll-Stroubos AM, Wiler B. Cardiac troponin-T immunoassay for diagnosis of acute myocardial infarction and detection of minor myocardial injury. *Clin Chem* 1994;40:900-7.
66. Bohlmeier TJ, Wu AHB, Perryman MB. Evaluation of laboratory tests as a guide to diagnosis and therapy of myositis. *Rheum Dis Clin NA* 1994;20:845-56.

67. Wu AHB, Kelly T, McKay C, Hill D. Definitive identification of an exceptionally high methanol concentration in an intoxication of a surviving infant: methanol metabolism by first-order elimination kinetics. *J Foren Sci* 1995;40:315-20.
68. Makowski GS, Richter JJ, Moore RE, Eisma R, Ostheimer D, Onoroski M, Wu AHB. An enzyme linked immunosorbent assay for urinary screening of fentanyl citrate (Sublimaze) abuse. *Ann Clin Lab Sci* 1995;25:169-78.
69. Wu AHB. Cardiac troponins T and I in coronary artery diseases. *AACC Endo* 1995;13:79-94.
70. Laios I, Caruk R, Wu AHB. Myoglobin clearance as an early indicator for rhabdomyolysis-induced acute renal failure. *Ann Clin Lab Sci* 1995;25:179-84.
71. Wu AHB, Forte E, Casella G, Sun K, Hemphill G, Foery R, Schanzenbach H. The CEDIA assays for screening drugs of abuse in urine and the affect of adulterants. *J Foren Sci* 1995; 40:614-8.
72. Wu AHB, Lane PJ. Meta-analysis in clinical chemistry: validation of cardiac troponin T as a marker for ischemic heart diseases. *Clin Chem* 1995;41:1228-33. *Clin Lab* 1996;42:788.
73. Wu AHB. Mechanism of interferences for gas chromatography/mass spectrometry analysis of urine for drugs of abuse. *Ann Clin Lab Sci* 1995;25:319-29.
74. Wu AHB. Near-patient and point-of-care testing of alcohol and drugs for abuse. *AACC Ther Drug Monit-Toxicol Update* 1995;16:225-42.
75. Sulkowski HA, Wu AHB, McCarter Y. In-vitro production of ethanol in urine by fermentation. *J Foren Sci* 1995;40:990-3.
76. Wu AHB, Abbas SA, Green S, Pearsall P, Dhakam S, Azar R, Onoroski M, Senaie A, McKay R, Waters D. The prognostic value of cardiac troponin T in patients with unstable angina. *Am J Cardiol* 1995;76:970-2.
77. Cao G, Verdon CP, Wu AH, Wang H, Prior RL. Automated oxygen radical absorbance capacity assay using the Cobas Fara II. *Clin Chem* 1995;41:1738-44.
78. Apple FS, Wu AHB, Valdes R Jr. Detection of myocardial injury by serum cardiac troponin T in hospitalized patients without myocardial infarction. *Scan J Clin Lab Invest* 1995;56:63-8.
79. Katz I, Wyndham L, Wu AHB, Apple FS, Valdes R. Cardiac troponin-T and diagnostic test evaluation. *Clin Chem* 1995;41:634-7.
80. Wu AHB, Feng YJ, Contois JH, Azar R, Waters D. Prognostic value of cardiac troponin I in chest pain patients. *Clin Chem* 1996;42:651-2. *Clin Lab* 1996;42:993-4.
81. Wu AHB. Cocaethylene. *AACC Ther Drug Monit-Toxicol Update* 1996;17:119-31.
82. Nicolau D, Wu AHB, Finnocharrio S, Nightingale C. Once-daily aminoglycoside dosing: impact on requests and costs for therapeutic drug monitoring. *Ther Drug Monit*;1996;18:263-6.
83. Wu AHB, Feng YJ, Contois JH, Pervaiz S. Comparison of myoglobin, creatine kinase-MB and cardiac troponin I for diagnosis of acute myocardial infarction. *Ann Clin Lab Sci* 1996;26:291-300.

84. Nicolau DP, Feng YJ, Wu AHB, Bernstein SP, Nightingale CH. Continuous arteriovenous hemofiltration (CAVH) in the swine: a model for the evaluation of drug clearances. *Lab Animal Sci* 1996;46:355-7.
85. Feld S, Li G, Wu A, Felli P, Amirian J, Vaughn WK, Gornet T, Swenson C, Smalling RW. Reduction of canine infarct size by bolus intravenous administration of liposomal prostaglandin E<sub>1</sub> (TLC C-53): comparison with control, placebo liposomes, and continuous intravenous infusion of prostaglandin E<sub>1</sub>. *Am Heart J* 1996;132:747-57.
86. Morris S, Wu AHB, Heller GV. New diagnostic approaches to patients with acute chest pain: role of cardiac imaging and biochemical markers. *Curr Opin Cardiol* 1996;11:386-93.
87. Abbas SA, Glazier JJ, Wu AHB, Green SF, Samedy H, Onoroski M, Pearsall LA, Waters DD, McKay RG. An analysis of the relative sensitivities of cardiac troponin T and of CK-MB in the detection of myocardial injury during percutaneous transluminal coronary angioplasty. *Clin Cardiol* 1996;19:782-6.
88. Nicolau DP, Feng YJ, Wu AHB, Bernstein SP, Nightingale CH. Evaluation of myoglobin clearance during continuous hemofiltration in a swine model of acute renal failure. *Int J Art Organs* 1996;19:578-81.
89. Ostheimer D, Cremese M, Wu AHB, Hill DW. Reduction in extraction efficiency of charged particles from the ion source as the cause of matrix effects in the GC/MS analysis of drugs. *J Anal Toxicol* 1997;21:17-22.
90. Tsongalis G, Anamani DE, Wu AHB. DNA fingerprinting for identification of urine specimen donors by polymerase chain reaction amplification typing of the HLA DQA locus. *J Foren Sci* 1996;41:1031-4.
91. Wu AHB, Feng YJ, Roper E, Herbert C, Schweizer R. Cardiac troponins T and I before and after renal transplantation. *Clin Chem* 1997;43:411-2.
92. Wu AHB, Bermes EW. Report of the third conference on education in clinical chemistry. *Clin Chem* 1997;43:167-73.
93. Wu AHB, Clive J. Impact of CK-MB testing policies on hospital length of stay and laboratory costs for myocardial infarction and chest pain patients. *Clin Chem* 1997;43:326-32.
94. Wu AHB. Reducing the inappropriate utilization of clinical laboratory tests. *Conn Med* 1997;61:15-21.
95. Pervaiz S, Anderson FP, Lohman TP, Lawson CJ, Feng YJ, Wasliewcz D, Contois CJ, Wu AHB. Comparative analysis of cardiac troponin I and CK-MB as markers of acute myocardial infarction. *Clin Cardiol* 1997;20:269-71.
96. Malliaros DP, Wong SS, Wu AHB, Camphbell J, Leonard H, Houser S, Berg M, Gornet T, Brown C, Feng YJ. Quantitative determination of theophylline in serum and plasma by automated chemiluminescent immunoassay. Comparison to other methods of analysis. *Ther Drug Monit* 1997;19:224-9.
97. Wu AHB, Feng YJ, Pajor A, Gornet TA, Wong SS, Forte E. Detection and interpretation of lysergic acid diethylamide (LSD) results by immunoassay screening of urine in various testing groups. *J Anal Toxicol* 1997;21:181-4.

98. Wu AHB. Use of cardiac markers as assessed by outcomes analysis. *Clin Biochem* 1997;30:339-50.
99. Cassella G, Wu AHB, Shaw BR, Hill DW. The analysis of thebaine in urine for detection of poppy seed consumption. *J Anal Toxicol* 1997;21:376-83.
100. Wu AHB, Feng YJ, Nadelmann J, Acampora M, Fiedler PN. Ectopic production of creatine kinase MB: updated evaluation by mass assays. *Clin Chem* 1997;43:2006-7.
101. Wu AHB. Analytical and clinical evaluation of new diagnostic tests for myocardial damage. *Clin Chim Acta* 1998;272:11-21.
102. Azar RR, McKay RG, Kiernan FJ, Seecharran B, Feng YJ, Fram DB, Wu AHB, Waters DD. Coronary angioplasty induces a systemic inflammatory response. *Am J Cardiol* 1997, 80:1476-1478.
103. Feng YJ, Chen C, Fallon JT, Ma L, Waters DD, Wu AHB. Comparison of cardiac troponin I, creatine kinase-MB, and myoglobin for detection of acute myocardial necrosis in a swine myocardial ischemic model. *Am J Clin Pathol* 1998;110:70-7.
104. Cheli CD, Morris DL, Kish L, Goldblat J, Neaman I, Allard WJ, Yeung KK, Wu AHB, Moore R, Chan DW, Fritsche HA, Schwartz MK, Very DL. Bayer Immuno 1 CA 15-3 assay: a highly precise and fully automated immunoassay for longitudinal monitoring of CA15-3 antigen levels in serum. *Clin Chem* 1998;44:765-72.
105. Giri S, Thompson PD, Taxel PM, Contois JH, Otvos J, Allen R, Ens G, Wu AHB, Waters DD. Low-dose estrogen improves serum lipids, homocysteine levels and fibrinolysis in elderly men. *Atheroscler*;1998;137:359-66.
106. Linfert DR, Wu AHB, Tsongalis G. The effect of pathologic substances and adulterants on the DNA typing of urine by the PM1 + DQ $\alpha$  assay kit. *J Foren Sci* 1998;43:1041-5.
107. Nicolau DP, Feng YJ, Wu AHB, Bernstein SP, Nightingale CH. Myoglobin clearance during continuous veno-venous hemofiltration with or without dialysis in a model of acute renal failure. *Int J Artif Organs* 1998;21:205-9.
108. Wu AHB, Linfert DR, Tsongalis G, McKay C. DNA typing of urine: confirmation of identity for samples submitted for drugs of abuse testing. *MRO Update* 1998;January: 11.
109. Mouser JF, Wu AHB, Herson VC. Aluminum contamination of neonatal parenteral nutrition solutions and additives. *Am J Health-Sys Pharm* 1998;55:1071-2.
110. Wu AHB. Date rape drugs and other substances producing amnesia. *AACC Ther Drug Monit-Toxicol Update*, 1998;19:149-64.
111. Olatidoye AG, Wu AHB, Feng YJ, Waters D. Prognostic role of troponin T versus I in unstable angina for cardiac events with meta-analysis comparing published studies. *Am J Cardiol* 1998, 81:1405-11.
112. Wu AHB, Feng YJ, Moore R, Apple FS, McPherson P, Buechler K, Bodor G. Characterization of cardiac troponin subunit release into serum following acute myocardial infarction, and comparison of assays for troponin T and I. *Clin Chem* 1998;44:1198-208.



113. Wu AHB. Integrity of urine specimens submitted for toxicologic analysis: adulteration, mechanisms of action, and laboratory detection. *Foren Sci Rev* 1998, 10:47-65.
114. Cremese M, Wu AHB, Cassella G, Rymut K, O'Connor E, Hill D. Improved GC/MS analysis of opiates with use of oxime-TMS derivatives. *J Foren Sci* 1998;43:1220-4.
115. Fitzmaurice TF, Brown C, Rifai N, Wu AHB, Yeo KTJ. False increase of cardiac troponin I with heterophilic antibodies. *Clin Chem* 1998;44:2212-4.
116. Wu AHB. Improving the utilization of clinical laboratory tests. *J Eval Clin Pract* 1998;4:171-81.
117. Wu AHB, Feng YJ. Biochemical differences between cTnT and cTnI and its significance for the diagnosis of acute coronary syndromes. *Eur Heart J* 1998;19suppl N:25-9.
118. Wu AHB. Cardiac markers: from enzymes to proteins, diagnosis to prognosis, laboratory to bedside. *Ann Clin Lab Sci* 1999;29:18-23.
119. Apple FS, Christenson RH, Valdes R Jr., Andriak AJ, Berg A, Duh SH, Feng YJ, Jortani SA, Johnson NA, Koplen K, Mascotti K, Wu AHB. Simultaneous rapid measurement of whole blood cardiac myoglobin, creatine kinase MB, and cardiac troponin I by the Triage Cardiac Panel for detection of myocardial infarction. *Clin Chem* 1999;45:199-205.
120. Wu AHB, Contois JH, Cole T. A reflex algorithm for use of cardiac risk assessment markers. *Clin Chim Acta* 1999;180:181-93.
121. Contois JH, Gillmor RG, Moore RE, Contois LRW, Macer JL, Wu AHB. Quantitative determination of cholesterol in lipoprotein fractions by electrophoresis. *Clin Chim Acta* 1999;282:1-14.
122. Wu AHB, Hill D, Crouch D, Hodnett NC, McCurdy H. Minimal standards for performance of toxicology tests and interpretation of results in legal cases. *J Foren Sci* 1999;44:516-22.
123. Wu AHB. A comparison of cardiac troponin T vs. cardiac Troponin I in patients with acute coronary syndromes. *Cor Art Dis* 1999;10:69-74.
124. Wu AHB. Laboratory and near patient testing for cardiac markers. *J Clin Ligand Assay* 1999;22:32-7.
125. Dati F, Panteghini M, Apple FS, Christenson RH, Mair J, Wu AH. Proposals from the IFCC Committee on Standardization of markers of Cardiac Damage (C-SMCD): strategies and concepts on standardization of cardiac marker assays. *Scan J Clin Invest* 1999;59 (suppl):113-23.
126. Wu AHB. Biochemical markers of cardiac damage: from traditional enzymes to cardiac-specific proteins. *Scan J Clin Lab Invest* 1999;59 (suppl):74-82.
127. Panteghini M, Apple FS, Christenson RH, Dati F, Mair J, Wu AH. Proposals from IFCC Committee on Standardization of Markers of Cardiac Damage (C-SMCD): recommendations on use of biochemical markers of cardiac damage in acute coronary syndromes. *Scan J Clin Lab Invest* 1999;59 (suppl):103-12.

128. Panteghini M, Apple FS, Christenson RH, Dati F, Mair J, Wu AH. Use of biochemical markers in acute coronary syndromes. IFCC Scientific Division, Committee on Standardization of Markers of Cardiac Damage. International Federation of Clinical Chemistry. *Clin Chem Lab Med* 1999;37:687-93.
129. Wu AHB, Apple FS, Gibler WB, Jesse RL, Warshaw MM, Valdes R Jr. National Academy of Clinical Biochemistry Standards of Laboratory Practice: Recommendations for use of cardiac markers in coronary artery diseases. *Clin Chem* 1999;45:1104-21.
130. Wu AHB, Ford L. Release of biochemical markers in acute coronary syndromes: ischemia or only necrosis? *Clin Chim Acta* 1999;284:161-71.
131. Wu AHB, Sexton K, Cassella G, Holtman V, Bristol B. Adulteration of urine by "Urine Luck." *Clin Chem* 1999, 45:1051-7.
132. Tsongalis GJ, Qu AHB, Silver H, Ricci A. Applications of forensic identity testing in the clinical laboratory. *Am J Clin Pathol* 1999;112(suppl 1):S93-103.
133. Christenson RH, Vaidya H, Landt Y, Bauer RS, Green SF, Apple FA, Azzazy HME, Jacob A, Magneson GR, Nag S, Wu AHB, Azzazy HME. Standardization of creatine kinase-MB (CK-MB) mass assays: the use of recombinant CK-MB as a reference material. *Clin Chem* 1999; 45:1414-23.
134. Wu AHB, Holtman V, Tsongalis GJ, Macer J. Homocysteine screening of a female Hispanic population. *Int J Mol Med* 1999;4:295-7.
135. Duca MD, Giri S, Wu AHB, Morris RS, Cyr GM, Ahlberg A, White M, Waters DD, Heller GV. Comparison of acute rest myocardial perfusion imaging and serum markers of myocardial injury in patients with chest pain syndromes. *J Nucl Cardiol* 1999; 6:570-6.
136. Wu AHB, Ghani F, Prigent F, Petry C, Armstrong G, Graff G. Reflex testing II: evaluation of an algorithm for use of cardiac markers in the assessment of emergency department patients with chest pain. *Clin Chim Acta* 1999:288:97-110.
137. Wu AHB. Obesity, anorexia, bulimia, and drugs associated with weight loss. *AACC Ther Drug Monit-Toxicol* 1999, 20:285-300.
138. Feng YJ, Draghi A, Linfert DR, Wu AHB, Tsongalis GJ. Polymorphisms in the genes for coagulation factors II, V and VII in patients with ischemic heart disease. *Arch Path Lab Med.* 1999; 123:1230-5.
139. Mockel M, Heller G, Berg K, Klefisch FR, Danne O, Muller C, Stork TV, Frei U, Wu AHB. The acute coronary syndrome diagnosis and prognostic evaluation by troponin I is influenced by the test system affinity to different troponin complexes. *Clin Chim Acta* 2000;293:139-55.
140. Wu AHB, Holtman V, Apple FS, Ricchiuti V, DiBello PM, Jacobsen D. Multicenter analytical evaluation of the automated IMx assay for total plasma homocysteine. *Ann Clin Lab Sci* 2000; 30:185-90.
141. Contois JH, Wu AHB, Li Z, Feroze AH, Grunenberger F, Haller J, Deslypere JP, deGroot L, Lammi-Keefe CJ. Distribution of serum apolipoproteins A-1 and B and lipoprotein(a) in European elderly: the Seneca Study. *Clin Chim Acta* 2000;295:1-12.

142. Ghani F, Wu AHB, Petry C, Armstrong G, Brown M, Graff L, Prigent F. Role of heart type fatty acid-binding protein in early detection of acute myocardial infarction. [Technical Brief] *Clin Chem* 2000; 46:718-9.
143. Wu AHB. Risk stratification of cardiac troponin in ischemic and non-ischemic cardiac diseases and procedures. *Rev Clin Biochem* 2000;21:79-88.
144. Azar RR, Aoun G, Fram DB, Waters DD, Wu AHB, Kiernan FJ. Relation of C-reactive protein and extent and severity of narrowing in patients with stable angina pectoris or abnormal exercise tests. *Am J Cardiol* 2000;86:205-7.
145. Stork T, Wu AHB, Muller-Bardorff M, Gareis R, Muller R, Frei U, Katus H, Mockel, M. Myoglobin in acute coronary syndrome patients with inconclusive ECG for early diagnosis and exclusion of acute myocardial infarction and cardiac troponin T for in-hospital prognosis. *Am J Cardiol* 2000; 86:1371-4.
146. Azar RR, Rinfret S, Theroux P, Stone PH, Dakshinamurthy R, Feng WJ, Wu AH, Range G, Waters DD. A randomized placebo-controlled trial to assess the efficacy of antiinflammatory therapy with methylprednisolone in unstable angina (MUNA trial). *Eur Heart J* 2000;21:2026-32.
147. Mockel M, Gerhardt W, Heller G Jr., Klefisch F, Danne O, Maske J, Muller C, Stork T, Frei U, Wu AHB. Validation of NACB and IFCC Guidelines for the use of cardiac markers for early diagnosis and risk assessment in patients with acute coronary syndromes. *Clin Chim Acta* 2001;303:167-179.
148. Hicks JM, Haeckel R, Price CP, Lewandrowski K, Wu AHB. Recommendations and opinions for the use of point-of-care testing for hospitals and primary care: summary of a 1999 symposium. *Clin Chim Acta* 2001;303:1-17.
149. Hill SS, Shaw BR, Wu AHB. The respiratory and nonrespiratory effects of plasticizers, antioxidants, and other contaminants in medical PBC tubing. *Clin Chim Acta* 2001, 304:1-8.
150. Christenson RH, Apple F, Bodor G, Bunk D, Dalluge J, Duh SH, Potter J, Welch M, Wu AHB, Kahn S. Standardization of cardiac troponin I assays: round robin of ten candidate reference materials. Standardization of ten reference materials. *Clin Chem* 2001;47: 431-7.
151. Christenson RH, Duh SH, Sanhai W, Wu AHB, Painter P, Apple FS, Morris DL. Characteristics of an albumin cobalt binding test for assessment of acute coronary syndrome patients: a multicenter study. *Clin Chem* 2001;47: 464-470.
152. Apple FS, Murakami M, Panteghini M, Christenson RH, Dati F, Mair J, Wu AHB. International survey on the use of cardiac markers. *Clin Chem* 2001;47:587-8.
153. Panteghini M, Gerhardt W, Apple FS, Dati F, Ravkilde J, Wu AH. Quality specifications for cardiac troponin assays. *Clin Chem Lab Med* 2001;39:174-8.
154. Wu AHB, Tsongalis GJ. Correlation of selected single nucleotide polymorphisms of coagulation factors to risk for cardiovascular disease. *Am J Cardiol* 2001; 87:1361-6.
155. Wu AHB, Morris DL, Fletcher DR, Apple FS, Christenson RH, Painter P. Analysis of the Albumin Cobalt Binding (ACB™) Test as an adjunct to cardiac troponin I for the early detection of acute myocardial infarction. *Cardiovasc Toxicol* 2001;1:147-152.

156. Sena S, Kazimi S, Wu AHB. False positive phencyclidine immunoassay result associated with venlafaxine and *o*-desmethylvenlafaxine. *Clin Chem* 2002;48:676-7.
157. Uettwiller-Geiger D, Wu AHB, Apple FS, Jevans AW, Venge P, Olson MD, Carte C, Woodrum DL, Roberts S, Chan S. Analytical performance of Beckman Coulter's Access® AccuTnI™ (Troponin I) in a multicenter evaluation. *Clin Chem* 2002;48:869-76.
158. Wu AHB, Boden WE, McKay RG. Long-term follow-up of patients with increased cardiac troponin concentrations following percutaneous coronary intervention. *Am J Cardiol* 2002;89:1300-2.
159. Maisel AS, Krishnaswamy P, Nowak RM, McCord J, Hollander JE, Duc P, Omland T, Storrow AB, Abraham WT, Wu AHB, Clopton P, Steg PG, Westheim A, Wold Knudsen C, Perez A, Kazanegra R, Herrmann HC, McCollough PA, for the BNP Multinational Study Investigators. Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. *N Engl J Med* 2002; 347:161-7.
160. McCullough PA, Nowak RM, McCord J, Hollander JE, Herrmann HC, Steg PG, Duc P, Westheim A, Omland T, Wold Knudsen C, Storrow AB, Abraham WT, Lamba S, Wu AHB, Perez A, Clopton P, Krishnaswamy P, Kazanegra R, Maisel AS, and for the BNP Multinational Study Investigators. B-Type Natriuretic Peptide and Clinical Judgment in Emergency Diagnosis of Heart Failure: Analysis From Breathing Not Properly (BNP) Multinational Study. *Circulation* 2002;106:416-22.
161. Wu AHB. A primer to urine drug testing. *IVD Tech* 2002;8(6):57-64.
162. Wieczorek SJ, Wu AHB, Christenson R, Rosano T, Hager D, Bailly K, Dahlen J, Chambers BS, Maisel A. A rapid B-type natriuretic peptide (BNP) assay accurately diagnoses left ventricular dysfunction and heart failure – a multi-center evaluation. *Am Heart J* 2002;144:834-839.
163. Apple FS, Wu AHB, Jaffe AS. European Society of Cardiology and American College of Cardiology guidelines for redefinition of myocardial infarction: how to use existing assays clinically and for clinical trials. *Am Heart J* 2002;144:981-6.
164. DeRoche M, Ingardia CJ, Guerette P, Wu AHB, LaSala CA, Mandavilli SR. The use of lamellar body counts to predict fetal lung maturity in pregnancies complicated by diabetes mellitus. *Am J Obstet Gynecol* 2002;187:908-12.
165. Wu AHB. B-type natriuretic peptide for congestive heart failure. *J Clin Ligand Assay* 2002;25:155-9.
166. Wieczorek SJ, Hager D, Barry MB, Kearney L, Ferrier A, Wu, AHB. Correlation of B-Type natriuretic peptide (BNP) to the 6-minute walk test in systolic congestive heart failure patients. *Clin Chim Acta* 2003;328:87-90.
167. Duncan B, Moyna NM, Heller GV, McGill C, Wieczorek S, Katten D, Wu A, Finta L, Velusamy M, Kelsey A, White CM. A 24-hour comparison of growth hormone concentrations in heart failure and normal subjects. *Pharmacother J* 2003;23:147-152.
168. Phillips JE, Bogema S, Fu P, Furmaga W, Wu AHB, Zic V, Hammett-Stabler C. Signify® ER Drug Screen Test Evaluation: comparison to Triage® Drug of Abuse Panel Plus TCA. *Clin Chim Acta* 2003;328:31-8.

169. Apple FS, Trinity E, Steen J, Prawner S, Wu AHB. Utilization of BNP monitoring for CHF in community hospital practice. *Clin Chim Acta* 2003;328:191-3.
170. Hill SS, Shaw BR, Wu AHB. Plasticizers, antioxidants, and other contaminants found in air delivered by PVC tubing used in respiratory therapy. *Biomed Chromatogr* 2003;17:250-62.
171. Wu AHB, Broussard LA, Hoffman RS, Kwong TC, McKay C, Moyer TP, Otten EM, Welch SL, Wax P. National Academy of Clinical Biochemistry. Laboratory Medicine Practice Guidelines. Recommendations for the use of laboratory tests to support the impaired and overdosed patients from the emergency department. *Clin Chem* 2003;49:357-79.
172. McCullough PA, Duc P, Omland T, McCord J, Nowak RM, Hollander JE, Herrmann HC, Steg PG, Westheim A, Wold Knudsen C, Storrow AB, Abraham WT, Lamba S, Wu AHB, Perez A, Clopton P, Krishnaswamy P, Kazanegra R, Maisel AS, for the BNP Multinational Study Investigators. B-Type natriuretic peptide and renal function in the diagnosis of heart failure: an analysis from the Breathing Not Properly Multinational Study. *Am J Kid Diseases* 2003;41:571-9.
173. McCullough PA, Hollander JE, Nowak RM, Storrow AB, Duc P, Omland T, McCord J, Hermann HC, Steg PG, Westheim A, Wold Knudsen C, Abraham WT, Lamba S, Wu AHB, Perez P, Clopton P, Krishnaswamy P, Kazanegra R, Maisel AS. Uncovering heart failure in patients with a history of pulmonary disease: rationale for the early use of B-type natriuretic peptide in the emergency department. *Acad Emerg Med* 2003;10:198-204.
174. Wu AHB, Bellantoni NF. Stability of cholesterol gall stones after 165 years of burial. *J Foren Sci* 2003;48:633-4.
175. Apple FS, Mukarami MM, Quist H, Wieczorek S, Wu AHB. Prognostic value of the Ortho Vitros cardiac troponin I assay in patients with symptoms of myocardial ischemia: risk stratification using European Society of Cardiology/American College of Cardiology recommended cutoff values. *Am J Clin Pathol* 2003;120:114-20.
176. Wu AHB, Smith AC, Mather JF, Duncan B, White CM, Ahlberg A, McGill C, Heller H. Biological variation for NT-pro- and B-type natriuretic peptides and implications for therapeutic monitoring of patients with congestive heart failure. *Am J Cardiol* 2003;92:628-31.
177. Maisel AS, McCord J, Nowak RM, Hollander JE, Wu AH, Duc P, Omland T, Storrow AB, Krishnaswamy P, Abraham WT, Clopton P, Steg G, Aumont MC, Westheim A, Knudsen CW, Perez A, Kamin R, Kazanegra R, Herrmann HC, McCullough PA. Breathing Not Properly Multinational Study Investigators. Bedside B-Type natriuretic peptide in the emergency diagnosis of heart failure with reduced or preserved ejection fraction. Results from the Breathing Not Properly Multinational Study. *J Am Coll Cardiol* 2003;41:2010-7.
178. Yeo KTJ, Wu AHB, Apple FS, Kroll MH, Christenson RH, Lewandrowski KB, Sedor FA, Butch AW. Multicenter Evaluation of the Roche NT-proBNP assay and comparison to Biosite Triage BNP assay. *Clin Chim Acta* 2003;338:107-115.

179. Wu AHB. Urine adulteration and substitution prior to drugs of abuse testing. *J Clin Ligand Assay* 2003;26:11-18.
180. Belenky A, Smith A, Zhang B, Lin S, Despres N, Wu AHB, Bluestein BI. The effect of class-specific protease inhibitors on the stabilization of B-type natriuretic peptide in human plasma. *Clin Chim Acta* 2004;340:163-72.
181. Chapman JF, Ashwood ER, Feld R, Wu AHB. Evaluation of two-dimensional cytometric lamellar body counts on the ADVIA 120 hematology system for estimation of fetal lung maturation. *Clin Chim Acta* 2004;340:85-92.
182. Panteghini M, Pagani F, Yeo KTJ, Apple FS, Christenson RH, Dati F, Mair J, Ravkilde J, Wu AHB. Evaluation of the imprecision at low-range concentration of the assays for cardiac troponin determination. *Clin Chem* 2004;50:327-32.
183. Wu AHB. Reflex testing III: efficient use of laboratory markers for anemia [Letter]. *Clin Chim Acta* 2004;343:241-3.
184. Wu AHB, Harrison A, Maisel AS. Reduced readmission rate for alternating diagnoses of congestive heart failure and pulmonary disease after implementation of B-type natriuretic peptide testing. *Eur J Heart Fail* 2004;6:309-12.
185. Wu AHB, Smith A. Biological variation of the natriuretic peptides and their role in monitoring patients with heart failure. *Eur J Heart Fail* 2004;6:355-8.
186. Panteghini M, Linsinger T, Wu AHB, Dati F, Apple FS, Christenson RH, Mair J, Schimmel H. Standardization of immunoassays for measurement of myoglobin in serum. Phase I: Evaluation of candidate secondary reference materials. *Clin Chim Acta* 2004; 341:65-72.
187. Mockel M, Danne O, Schmidt A, Muller C, Dietz R, Wu AHB. Reference values for cardiac troponin I and T in a goal-oriented concept of health: cardiac marker values in a series of outpatients without acute coronary syndromes. *Clin Chim Acta* 2004;342:83-6.
188. Wu AHB Packer M, Smith A, Bijou R, Fink F, Mair J, Wallentin L, Feldcamp CS, Haverstick DM, Ahnadi CE, Grant A, Despres N, Bluestein B, Ghani F. Analytical and clinical evaluation of the Bayer ADVIA Centaur automated B-type natriuretic peptide assay in patients with heart failure: a multisite study. *Clin Chem* 2004;50: 867-73.
189. Wu AHB. Quality specifications in thyroid diseases. *Clin Chim Acta* 2004;346:73-7.
190. Wu AHB, Smith A, Christenson RH, Murakami MM, Apple FS. Evaluation of a point-of-care assay for cardiac markers for patients suspected of acute myocardial infarction. *Clin Chim Acta* 2004;346:211-9.
191. Maisel AS, Cloptom P, Krishnaswamy P, Nowak, RM, McCord J, Hollander JE, Duc P, Omland T, Storrow AB, Abraham WT, Wu AHB, Steg G, Westheim A, Wold Knudsen C, Perez A, Kazanegra R, Bhalla V, Hermann HC, Aumont MC, McCullough PA. The impact of age, race and gender on the ability of B-type natriuretic peptide to aid in the emergency diagnosis of heart failure: results from the Breathing Not Properly (BNP) Multinational Study. *Am Heart J* 2004;147:1078-84.

192. Wu AHB, Smith A, Apple FS. Optimum blood collection intervals for B-type natriuretic peptide testing in heart failure patients. *Am J Cardiol* 2004;93:1562-3.
193. Wu AHB, Omland T, Duc P, McCord J, Nowak RM, Hollander JE, Herrmann HC, Steg PG, Wold Knudsen C, Storrow AB, Abraham WT, Perez A, Kamin R, Clopton P, Maisel AS, McCullough PA, for the Breathing Not Properly Multinational Study Investigators. The effect of diabetes on B-type natriuretic peptide concentrations in patients with acute dyspnea: an analysis from the Breathing Not Properly Multinational Study. *Diabetes Care* 2004;27:2398-2404.
194. Knudsen CW, Omland T, Clopton P, Westheim A, Abraham WT, Storrow AB, McCord J, Nowak RM, Aumont MC, Duc P, Hollander JE, Wu AHB, McCullough PA, Maisel AS. Diagnostic value of B-type natriuretic peptide and chest radiographic findings in patients with acute dyspnea. *Am J Med* 2004;116:363-8.
195. Duncan B, Wiecek S, Wu A, Moyna NM, Heller GV, White CM. A 24-hour comparison of whole blood B-type natriuretic peptide. Concentrations in heart failure and normal subjects. *N Engl J Med* 2004;351:30-3.
196. Yaworsky DC, Wu AHB, Hill DW. The use of plasma metanephrine to normetanephrine ratio to determine epinephrine poisoning. *Clin Chim Acta* 2005;353:31-44.
197. Apple FS, Mair J, Ravkilde J, Christenson RH, Franca P, Tate J, Wu AHB, Panteghini M, Jaffe A. Quality specifications for B-type natriuretic peptide assays. *Clin Chem* 2005;51:486-91.
198. Tang WHW, Philip K, Hazen SL, Cole CE, Pepoy M, Smith A, Neale S, Van Lente F, Francis GS, Wu AHB. Comparative sensitivities between different plasma B-type natriuretic peptide assays in patients with minimally symptomatic heart failure: implications for population screening. *Clin Corner* 2005;7(suppl 1):S18-S24.
199. McCord J, Nowak RM, Jacobsen G, Sallach JA, Wu AH, Perez A, Omland T, Knudsen CW, Westheim A, Duc P, Steg PG, Hollander JE, Herrmann HC, Storrow AB, Abraham WT, Lamba S, McCullough PA, Maisel A. B-type natriuretic peptide levels in patients in the emergency department with possible heart failure and previous stable angina pectoris and/or healed myocardial infarction. *Am J Cardiol* 2005;96:1370-3.
200. Apple FS, Wu AHB, Mair J, Ravkilde J, Panteghini M, Tate J, Pagani F, Christenson RH, Mockel R, Danne O, Jaffe AS. Future biomarkers for detection of ischemia and risk stratification in acute coronary syndrome. *Clin Chem* 2005;51:810-824.
201. Wu AHB. Markers for early cardiovascular disease detection. *Scan J Clin Lab Invest* 2005;65(suppl 240):112-121.
202. Knudsen CW, Clopton P, Westheim A, Klemsdal TO, Wu A, Duc P, McCord J, Nowak RM, Hollander JE, Storrow AB, Abraham WT, McCullough PA, Maisel A, Omland T. Predictors and significance of an elevated B-type natriuretic peptide concentration in dyspneic patients without a diagnosis of heart failure: an analysis from the Breathing Not Properly Multinational Study. *Ann Emerg Med* 2005;45:573-80.
203. Knudsen CW, Omland T, Clopton P, Westheim A, Wu AH, Duc P, McCord J, Nowak RM, Hollander JE, Storrow AB, Abraham WT, McCullough PA, Maisel A.

- Impact of atrial fibrillation on the diagnostic performance of b-type natriuretic peptide concentration in dyspneic patients an analysis from the breathing not properly multinational study. *J Am Coll Cardiol* 2005;46:838-44.
204. Apple FS, Parvin CA, Buechler K, Christenson RH, Wu AHB, Jaffe AS. Validation of the 99th percentile cutoff for cardiac troponin monitoring for detection of myocardial infarction. *Clin Chem* 2005;51:2198-2200.
  205. Singer M, Mirhej G, Shaw S, Salaheen H, Vivian J, Hastings E, Rohena L, Jennings D, Navarro J, Santelices C, Wu AHB, Smith A, Perez A. When the drug of choice is a drug of confusion: embalming fluid use in inner city Hartford CT. *J Ethn Sub Abuse* 2005; 4:73-96.
  206. Wu AHB, Omland T, McCord J, Nowak RM, Hollander JE, Duc P, Storrow AB, Abraham WT, Clopton P, Steg G, Knudsen CW, Kazanegra R, Herrmann HC, Maisel AS, McCullough PA. The relationship of B-type natriuretic peptide and anemia in patients with and without heart failure: a substudy from the Breathing Not Properly (BNP) Multinational Study. *Am J Hematol* 2005;80:174-80.
  207. Ruaño G, Thompson PD, Windemuth A, Smith A, Kocherla M, Holford TR, Seip R, Wu AHB. Physiogenomic analysis links serum CK activities during statin therapy to vascular smooth muscle homeostasis. *Pharmacogen* 2005;6:865-72.
  208. Strunk A, Bhalla V, Clopton P, Nowak RM, McCord J, Hollander JE, Duc P, Storrow AB, Abraham WT, Wu AHB, Steg G, Perez A, Kazanegra R, Herrmann HC, Aumont MC, McCullough PA, Maisel A, for the BNP Multinational Study Investigators. Impact of the history of congestive heart failure on the utility of B-type natriuretic peptide in the emergency diagnosis of heart failure: Results from the Breathing Not Properly Multinational Study. *Am J Med*;119:69.e1-69.e11, 2006.
  209. Kupchak P, Wu, AHB, Ghani F, Newby, LK, Ohman EH, Christenson RH. The influence of imprecision on receiver-operating characteristic curve analysis for cardiac markers. *Clin Chem* 2006;52: 752-3.
  210. Wu AHB. Point-of-care testing for conventional cardiac markers. *J Point Care* 2006;5:20-4.
  211. Ruano G, Makowski G, Windemuth A, Kocherla M, Weiss S, Goethe JW, Bower B, Wu AHB, Thompson P. High carrier prevalence of deficient and null alleles of CYP2 genes in a major USA hospital: implications for personalized drug safety. *Person Med* 2006;3:131-7.
  212. Daniels LB, Clopton P, Bhalla V, Krishnaswamy P, Nowak RM, McCord J, Hollander JE, Duc P, Omland T, Storrow AB, Abraham WT, Wu AHB, Steg PG, Westheim A, Wold Knudsen C, Perez A, Kazanegra R, Hermann HC, McCullough PA, Maisel AS. How obesity affects the cut-points for B-type natriuretic peptide in the diagnosis of acute heart failure: results from the Breathing Not Properly Multinational Study. *Am Heart J* 2006;151:999-1005.
  213. Wu AHB. A selected history and future of immunoassay development and applications in clinical chemistry. *Clin Chim Acta* 2006;369:119-24.
  214. Christenson RH, Duh SH, Apple FS, Bodor GS, Bunk DM, Panteghini M, Welch MJ, Wu AHB, Kahn SE, for the American Association for Clinical Chemistry Cardiac



- Troponin I Standardization Committee. Toward standardization of cardiac troponin I measurements part II: assessing commutability of candidate reference materials and harmonization of cardiac troponin I assays. *Clin Chem* 2006;52:1685-92.
215. Wu AHB, Fukushima F, Puskas R, Todd J, Goix P. Development and preliminary clinical validation of a high sensitivity assay for cardiac troponin using a capillary flow (single molecule) fluorescence detector. *Clin Chem* 2006;52:2157-9.
  216. Wu AHB. Serial testing of B-type natriuretic peptide and NTpro-BNP for monitoring therapy of heart failure: the role of biological variation in interpretation of results. *Am Heart J*. 2006;152:828-34.
  217. Wu AHB. Plasma BNP/NT-proBNP assays: what do they target and what other things might they recognize? *Heart Fail Clin* 2006;2:291-8.
  218. Wang P, Stone JA, Chen KH, Gross SF, Haller CA, Wu AHB. Hydrolysis methods impacts recovery and detection of urine opiates. *J Anal Toxicol* 2006;30:570-6.
  219. Yarlagadda S, Rajendran P, Miss JC, Banki NM, Kopelnik A Wu AHB, Ko N, Gelb AW, Lawton MT, Smith WS, Young W, Zaroff J. Cardiovascular predictors of inpatient mortality after subarachnoid hemorrhage. *Neurocrit Care* 2006;5:102-7.
  220. Wu AHB, Schultz K, Gomez C, Smith A, Tabas JA. Laboratory testing for salicylate resistance. *J Clin Ligand Assay* 2006;29:60-3.
  221. Fiebig E, Wu AHB, Krombach J, Tang J, Nguyen KA, Toy P. Transfusion Related Acute Lung Injury (TRALI) and transfusion associated circulatory overload (TACO)- mutually exclusive or coexisting entities [Letter]? *Transfus* 2007;47:171-2.
  222. Bibbins-Domingo K, Gupta R, Na B, Wu AHB, Schiller NB, Whooley MA. N-terminal pro-B-type natriuretic peptide and incident heart failure in ambulatory patients with coronary disease: data from the Heart and Soul Study. *JAMA* 2007; 297:169-176.
  223. Corteville DC, Bibbins-Domingo K, Wu AHB, Ali S, Schiller NB, Whooley MA. NT-proBNP rules out ventricular dysfunction in patients with coronary disease: Data from the Heart and Soul Study *Arch Int Med* 2007;167:483-9.
  224. Tran MN, Wu AHB, Hill DW. Alcohol dehydrogenase and catalase content in perinatal infant and adult livers: potential influence on neonatal ethanol metabolism. *Tox Letters* 2007;169:245-52.
  225. Morrow DA, Cannon CP, Jesse RL, Newby LK, Ravkilde J, Storrow AB, Wu AHB, Christenson RH. National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines: clinical characteristics and utilization of biochemical markers in acute coronary syndromes. *Clin Chem* 2007;53:552-74 and *Circulation* 2007; 115:e356-75.
  226. Apple FS, Jesse RL, Newby LK, Wu AHB, Christenson RH. National Academy of Clinical Biochemistry and IFCC Committee for Standardization of Markers of Cardiac Damage Laboratory Medicine Practice Guidelines: analytical issues for biomarkers of acute coronary syndromes. *Clin Chem* 2007;53:547-51 and *Circulation* 2007;115:e352-5.
  227. Joelson D, Wu AHB, Fiebig E. Need for erythrocyte folate measurements in the post folic acid supplementation among indigent populations. *Arch Path Lab Med* 2007;131:477-80.

228. Wu AHB. The use of genetic and non-genetic factors in warfarin dosing algorithms. *Pharmacogen* 2007;8:851-61.
229. Apple FS, Wu AHB, Jaffe AS, Panteghini M, Christenson RH. National Academy of Clinical Biochemistry and IFCC Committee for Standardization of Markers of Cardiac Damage Laboratory Medicine Practice Guidelines: analytical issues for biomarkers of heart failure. *Circulation* 2007 116:e95-8 and *Clin Biochem* 2008;41:222-6.
230. Tang WHW, Francis GS, Morrow DA, Newby LK, Cannon CP, Jesse RL, Storrow AB, Christenson RH. Committee members: Christenson RH, Apple FS, Cannon CP, Francis GS, Jesse RL, Morrow DA, Newby LK, Ravkilde J, Storrow AB, Tang WHW, Wu AHB. National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines: clinical utilization of cardiac biomarker testing in heart failure. *Circulation* 2007;116:e99- 109.
231. Januzzi JL Jr, Peacock WF, Maisel AS, Chae CU, Jesse LR, Baggish AL, O'Donoghue M, Sakhuja R, Chen AA, van Kimmenade RRJ, Lewandrowski KB, Lloyd-Jones DM, Wu AHB. Measurement of the interleukin family member ST2 in patients with acute dyspnea: results from the PRIDE (Pro-Brain Natriuretic Peptide Investigation of Dyspnea in the Emergency Department) Study. *J Am Coll Cardiol* 2007;50:607-13.
232. Desai AS, Bibbins-Domingo K, Shlipak MG, Wu ALH, Ali S, Whooley MA. Association between anemia and N-terminal pro-B-type natriuretic peptide (NT-proBNP) inpatients without clinical heart failure: findings from the Heart and Soul Study. *Eur J Cardiac Failure* 2007;9:886-91.
233. Ruano G, Thompson PD, Windemuth A, Dande A, Kocherla M, Seip RL, Smith A, Holford TR, Wu AHB. Physiogenomic association of statin-related myalgia to serotonin receptors. *Muscle Nerve* 2007;36:329-35.
234. Wu AHB. Early detection of acute coronary syndromes and risk stratification by multibiomarker analysis. *Biomark Med* 2007, 1:45-58.
235. Brown AM, Wu AHB, Clopton P, Robey JL, Hollander JE. ST2 in emergency department chest pain patients with potential acute coronary syndromes. *Ann Emerg Med* 2007;50:153-8.
236. Lewandrowski L, Januzzi J, Green S, Tannous B, Wu AHB, Smith A, Wong A, Murakami MM, Kaczmarek J, Apple FS, Miller WL, Hartman K, Jaffe AS. Multi-center validation of the Response Biomedical Corporation RAMP NT-proBNP assay with comparison to the Roche Diagnostics Elecsys proBNP assay. *Clin Chim Acta* 2007;396:20-4.
237. Wu AHB, Apple FS, Jaffe AS, Jesse RL, Morrow DA, Newby K, Ravkilde J, Francis GL, Christenson RH. National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines: use of cardiac troponin and the natriuretic peptides for etiologies other than acute coronary syndromes and heart failure. *Clin Chem* 2007;53:2086-96.
238. Wu AHB, Smith A, McComb R, Bowers, Jr., GN, Makowski GS, McKay C, Vena J, McDonagh J, Hopfer S, Sena SF, Malkus HL, Forte E, Kelly K. State-wide

- hospital clinical laboratory plan for measuring cholinesterase activity for individuals suspected of exposure to nerve gas chemical weapons. *Clin Toxicol* 2008;46:1-7.
239. Wu AHB, Jaffe AS. The clinical need for high sensitivity cardiac troponin assays for ACS and the role for serial testing. *Am Heart J* 2008;155:208-14.
240. Wu AHB, Wang P, Smith A, Haller C, Drake K, Linder MW, Valdes, RL Jr. Effect of ethnicity and a comparison of dosing algorithms for warfarin using genotyping for CYP 2C9 and the vitamin K reductase complex 1. *Pharmacogen* 2008;9:169-78.
241. Luckenbill KN, Christenson RH, Jaffe AS, Mair J, Ordonez-Llanos J, Pagani F, Tate JR, Wu AHB, Ler R, Apple FS. Cross-reactivity of BNP, NT-proBNP and proBNP in commercial BNP and NT-proBNP assays: preliminary observations. *Clin Chem* 2008;54:619-21.
242. Ruano G, Thompson PD, Villagra D, Bower B, Kocherla M, Yazdanpanah G, Seip RL, Windemuth A, Holford TR, Wu AHB. High carrier prevalence of combinatorial CYP2C9 and VKORC1 genotypes associated with risk of warfarin bleeding. *Person Med* 2008;5:225-32.
243. Peacock WF, De Marco T, Fonarow GC, Diercks D, Wynne D, Apple FS, Wu AHB, for the ADHERE Investigators. Cardiac troponin and outcome in acute heart failure. *N Engl J Med* 2008;358:2117-26.
244. Luckenbill KN, Jaffe AS, Mair J, Ordonez-Llanos J, Wu AHB, Murakami MM, Christenson RH, Pagani F, Saenger AK, Ler R, Apple FS. Cross-reactivity of BNP, NT-proBNP and proBNP in commercial NT-proBNP assays: a substudy from the IFCC Committee for Standardization of Markers of Cardiac Damage. *Clin Chem* 2008;54:619-21.
245. Klutts JS, Wu AHB, Smith A, Yen-Lieberman B, Binder Sr, Gronowski AM. Diagnostic performance of a new automated method for heterophile antibody testing in adults and children. *Diag Microbiol Infect Dis* 2008;61:351-3.
246. Wang P, Huang L, Davis L, Swartzman A, Roth B, Stone J, Wu AHB. A hydrophilic-interaction chromatography tandem mass spectrometry method for quantitation of serum s-adenosylmethionine in HIV-positive patients. *Clin Chim Acta* 2008;396:86-8.
247. Wu AHB, Lu A, Todd J, Moecks J, Wians F. Short- and long-term biological variation in cardiac troponin I with a high-sensitivity assay: implications for clinical practice. *Clin Chem* 2009;55:52-8.
248. Wu AHB, Smith A, Wians FH. Interpretation of creatine kinase and aldolase for statin-induced myopathy: reliance on serial testing based on biological variation. *Clin Chim Acta* 2009;399:109-111.
249. Wu AHB, Agee SJ, Lu AQ, Todd J, Jaffe AS. Specificity of a high sensitivity cTnI assay utilizing single molecule counting technology. *Clin Chem* 2009;55:196-8.
250. Wu AHB. Interpretation of high sensitivity cardiac troponin I results: reference to biological variability in patients who present to the emergency room with chest pain. *Clin Chim Acta* 2009; 401:170-4.

251. Wu AHB, Shea E, Lu QT, Minyard J, Bui K, Hsu JCY, Agee SJ, Todd J. Short- and long-term cTnI analyte stability in plasma and serum from healthy volunteers using an ultra-sensitive, single-molecule counting assay. *Clin Chem* 2009;55:2057-9.
252. Drees JC, Stone JA, Olson KR, Gelb AM, Meier KH, Wu AHB. The clinical utility of a seizure panel to detect common drugs involved in drug-induced seizures using LC-MS/MS. *Clin Chem* 2009;55:126-33.
253. International Warfarin Pharmacogenetics Consortium. Improved warfarin dosing with a global pharmacogenetic algorithm. *N Engl J Med* 2009;360:753-64.
254. Wu AHB, Babic N, Yeo JT. Implementation of pharmacogenomics into the clinical practice of therapeutics: issues for the clinician and the laboratorian. *Person Med* 2009;6:315-27.
255. Wu AHB, Schafer A. Mild positive hCG in a perimenopausal female: normal, malignancy, or phantom? *Lab Med* 2009;40:463-6.
256. Singh HS, Bibbins-Domingo K, Ali S, Wu AHB, Schiller NB, Whooley MA. N-Terminal pro-B-type natriuretic peptide and inducible ischemia in the Heart and Soul Study. *Clin Cardiol* 2009;32:447-53.
257. Wu AHB, Smith A, Rame E, Wians FH, Minard F, Giuliani I, Larue C. Analytical assay characterization for pro-B-type natriuretic peptide. *Clin Chim Acta* 2009;409:143-4.
258. Pahle AS, Sorli D, Omland T, Knudsen WC, Westheim AS, Wu AH, Steg PG, McCord J, Nowak RM, Hollander JE, Storrow AB, Abraham WT, McCullough PA, Maisel A. Impact of systemic hypertension on the diagnostic performance of B-type natriuretic peptide in patients with acute dyspnea. *Am J Cardiol* 2009;104:966-71.
259. Drees JC, Stone JA, Wu AHB. Morbidity involving the hallucinogenic designer amine MDA and 2C-I. *J Foren Sci* 2009;54:1485-7.
260. Rame JE, Tam SW, McNamara D, Worcel M, Sabolinski ML, Wu AHB, Dries DL. Dysfunctional corin I555 (P568) allele is associated with impaired BNP processing and adverse outcomes in African-Americans with systolic heart failure: results from the genetic risk assessment in heart failure A-HeFT Sub-Study. *Circ Heart Failure* 2009;2:541-8.
261. Hsieh PC, Rogers AM, Na B, Wu AHB, Schiller NB, Whooley MA. Prevalence and prognostic significance of incidental cardiac troponin T elevation in ambulatory patients with stable coronary artery disease: data from the Heart and Soul Study. *Am Heart J* 2009;158:673-9.
262. Benowitz NL, Sschults K, Haller C, Wu AHB, Dains K, Jacob P. Prevalence of smoking assessed biochemically in an urban public hospital: rationale for routine cotinine screening. *Am J Epidemiol* 2009;170:885-91.
263. Melanson SEF, Baskin L, Magnani BJ, Kwong TC, Dizon A, Wu AHB. Interpretation and utility of drug of abuse immunoassays: lessons from laboratory drug testing surveys. *Arch Path Lab Med* 2010;134:735-9.
264. Ureda N, Ruan W, French D, Wu AHB. Lack of  $\gamma$ -hydroxybutrate prevalence among an urban emergency department population. *J Anal Toxicol* 2010;34:110-11.

265. French D, Stone JA, Chang JS, Wu AHB. Choosing the right benzodiazepine assay: impact on clinical decision making. *Lab Med* 2010;41:196-200.
266. Christenson RH, Duh SH, Wu AHB, Smith A, Abel G, deFilippi C, Wang S, Adourian A, Adiletto C, Gardiner P. Multi-center determination of galectin-3 assay performance characteristics: anatomy of a novel assay for use in heart failure. *Clin Biochem* 2010, 43:683-90.
267. Dries DL, Ky B, Wu AH, Rame JE, Putt ME, Cappola TP. Simultaneous assessment of unprocessed ProBNP1-108 in addition to processed BNP32 improves identification of high-risk ambulatory patients with heart failure. *Circ Heart Fail* 2010;3:220-7.
268. Maisel AS, Muller C, Nowak R, Peacock WF, Landsberg JW, Ponikowski P, Mockel M, Hogan C, Wu AHB, Richards M, Clopton P, Filippatos GS, Di Somma S, Anand I, Ng L, Danies LB, Neath SX, Christenson C, Potocki M, McCord J., Terracciano G, Kremastinos D, Hartman O, von Haehling S, Bergmann A, Morgenthaler NG, Anker SD. Mid-region prohormone markers for the diagnosis and acute dyspnea: results from the BACH (biomarkers in acute heart failure) Trial. *J Am Coll Cardiol* 2010;55:2062-76.
269. Hickman PE, Potter JM, Aroney C, Koerbin G, Southcott E, Wu AHB, Roberts MS. Cardiac troponin may be released by ischemia alone, without necrosis. *Clin Chim Acta* 2010;411:318-23.
270. Limdi NA, Wadelius M, Cavallari L, Eriksson N, Crawford DC, Lee MTM, Chen CH, Motsinger-Reif A, Sagreya H, Liu N, Wu AHB, Gage BF, Jorgensen A, Pirmohamed N, Shin JG, Suarez-Kurtz G, Kimmel SE, Johnson JA, Kein TE, Wagner MJ on behalf of the IWPC. Warfarin pharmacogenomics: a single VKORC1 polymorphism is predictive of dose across three racial groups. *Blood* 2010;115:3827-34.
271. Lynch KL, Breaud A, Wu AHB, Clarke W. Performance evaluation of three liquid chromatography mass spectrometry methods for broad spectrum drug screening. *Clin Chim Acta* 2010;411:1474-81.
272. Pratt VM, Zehnbaauer B, Wilson JA, Baak R, Babic N, Bettinotti M, Buller A, Butz K, Campbell M, Civalier C, El-Badry A, Farkas DH, Lyon E, Mandal S, McKinney J, Muralidharan K, Noll LA, Sander T, Shabber J, Smith C, Telatar M, Toji L, Varivan A, Vance C, Weck K, Wu AHB, Yeo KT, Zeller M, Kalman L. Characterization of 107 genomic DNA reference materials for *CYP2D6*, *CYP2C19*, *CYP2C9*, *VKORC1* and *UGT1A1*: A GeT-RM and Association for Molecular Pathology collaborative project. *J Mol Diag* 2010, 12:835-46.
273. Ruaño G, Thompson PD, Kane JP, Pullinger CR, Windemuth A, Seip RL, Kocherla M, Holford TR, Wu AHB. Physiogenomic analysis of statin-treated patients: domain specific counter effects within the ACACB gene on LDL cholesterol? *Pharmacogen* 2010;11:959-71.
274. Wu AHB, Drees JC, Wang H, VandenBerg SR, Lal A, Henner WD, Pillai R. Gene expression profiles identify the tissue of origin for metastatic brain cancers. *Diagn Pathol* 2010, 5:26-32.

275. Wu AHB, Lewandrowski KB, Gronowski A, Grenache D, Sokoll S, Magnani B. Antiquated tests within the clinical laboratory. *Am J Managed Care* 2010;16:e220-7.
276. Frymoyer A, Shugarts S, Bromwne M, Wu AH, Frassetto L, Benet LZ. Effect of single-dose rifampin on the pharmacokinetics of warfarin in healthy volunteers. *Clin Pharm Ther* 2010, 88:540-7.
277. French D, Gorgi AW, Ihenetu KU, Weeks MA, Lynch KL, Wu AHB. Vitamin D status of county hospital patients assessed by the Diasorin Liaison 25-hydroxyvitamin D assay. *Clin Chim Acta* 2011;412:258-62.
278. Glaser R, Peacock WF, Shih J, Wu AHB, Muller R, Mockel M, Apple FS. Placental growth factor and B-type natriuretic peptide provide superior risk stratification of emergency room patients with suspected acute coronary syndrome above traditional markers and risk factors. *Am J Cardiol*; 2011; 107:821-6.
279. French D, Branch J, Wu AHB, Winston L, Fiebig E. A case of a fast drop in lactate. *Am J Emerg Med* 2011;29:351-3.
280. French D, Armenian P, Ruan W, Wong A, Drasner K, Wu AHB. Retrospective determination of serum verapamil concentration before and after Intralipid therapy in an overdose case. *Clin Toxicol* 2011;49:340-4.
281. Lorizio W, Rugo H, Beattie MS, Tchu S, Melese T, Melisko M, Wu AH, Lawrence H, Nickoloff M, Ziv E. Pharmacogenetic testing affects choice of therapy among women considering tamoxifen treatment. *J Genom Med* 2011;3:64-72.
282. Kostenko L, Kjer-Nielsen L, Nicholson I, Hudson F, Lucas A, Foley B, Chen K, Lynch K, Nguyen J, Wu AHB, Tait BD, Holdsworth R, Mallal S, Rossjohn J, Bharadwaj M, McCluskey J. Rapid screening for detection of HLA-B57 and B58 in prevention of drug hypersensitivity. *Tissue Antigens* 2011;78:11-20.
283. French D, Wu A, Lynch K. Hydrophilic interaction LC-MS/MS analysis of opioids in urine: significance of glucuronide metabolites. *Bioanal* 2011;3:2603-12.
284. Frankenstein L, Wu AHB, Hallermayer K, Wians FH, Giannitsis E, Katus HA. Biological variation and reference change value of high sensitivity troponin T in healthy individuals during short and intermediate follow-up periods. *Clin Chem* 2011, 57: 1068-71.
285. Hall L, Wilson JA, Bernard K, Carbone MP, El Murbarak HS, Hallam SE, Klein RD, Pancholi P, Schoonmaker MM, Spector EB, Vitzzka P, Boonyaratanakornkit J, Bryant B, Dong J, Emmadi R, Furtado MR, Lacbawan F, Martinze-Murillo F, Schutzbank TE, Selvarangan R, Shyamala V, Williams LO, Wu A. Establishing molecular testing in clinical laboratory environments; proposed guideline. CLSI document MM19-P. Wayne, PA: Clinical and Laboratory Standards Institute; 2011.
286. French D, Smith A, Powers MP, Wu AH. KRAS mutation detection in colorectal cancer by a commercially available gene chip array compares well with Sanger sequencing. *Clin Chim Acta* 2011;412:17-8.
287. Taub PR, Fields JD, Wu AHB, Miss JC, Lawton MT, Smith WS, Young WL, Zaroff JG, Ko NU. Elevated BNP is associated with vasospasm-induced cerebral infarction following aneurismal subarachnoid hemorrhage. *Neuro Crit Care* 2011,15:13-18.

288. Ky B, French B, McCloskey K, Rame JE, McIntosh E, Shahi P, Dries DL, Tang WHW, Wu AHB, Fang JC, Boxer R, Sweitzer NK, Levy WC, Goldberg LR, Jessup M, Cappola TP. High-sensitivity ST2 for prediction of adverse outcomes in chronic heart failure. *Circ Heart Fail* 2011;4:180-7.
289. Ky B, French B, Levy W, Sweitzer N, Fang J, Wu AH, Goldberg L, Jessup M, Cappola T. Multiple markers for risk prediction in chronic heart failure. *Circ Heart Fail Epub*, Mar 2012.
290. Maisel A, Xue Y, Shah K, Mueller C, Nowak R, Peacock WF, Ponikowski P, Mockel M, Hogan C, Wu AHB, Richards M, Clopton P, Filippatos GS, Di Somma S, Anand I, Ng L, Daniels LB, Neath SX, Christenson R, Potocki M, McCord J, Terracciano G, Hartmann O, Bergmann A, Morgenthaler NG, Anker SD. Increased 90-day mortality in acute heart failure patients with elevated copeptide: secondary results from the Biomarkers in Acute Heart Failure (BACH) Study. *Circ Heart Failure* 2011;4:613-20.
291. Madlensky L, Natarajan L, Tchu S, Pu M, Mortimer J, Flatt SW, Parker BA, Wu AHB, Pierce JP. Tamoxifen metabolite concentrations, CYP2D6 genotype and breast cancer outcomes. *Clin Pharmacol Ther* 2011;89:718-25.
292. Schwartz JB, Kane L, Moore K, Wu AHB. Failure of pharmacogenetic-based dosing algorithms to identify older patients requiring low daily doses of warfarin. *J Am Med Dir Assoc* 2011;12:633-8.
293. Grenert JP, Smith A, Ruan W, Pillai R, Wu AHB. Gene expression profiling from formalin-fixed, paraffin-embedded tissue for tumor diagnosis. *Clin Chim Acta* 2011;412:1462-4.
294. Gerona RRL, Birdsall E, Wu AHB. Non-targeted analysis of synthetic cannabinoids in two intoxication cases involving herbal incense products. *Am J Clin Pathol* 2011;136:474-5.
295. Ruano G, Windemuth A, Wu AHB, Kane JP, Malloy MJ, Pullinger CR, Kocherla M, Bogaard K, Gordon BR, Holford TR, Gupta A, Seip R, Thompson P. Mechanisms of statin-induced myalgia assessed by physiogenomic associations. *Atherosclerosis* 2011, 218:451-6.
296. Peacock WF, Nowak R, Christenson R, DiSomma S, Neath SX, Hartman O, Mueller C, Ponikowski P, Mockel M, Hogan C, Wu AHB, Richards M, Filippatos GS, Ander I, Ng L, Daniels LB, Morgenthaler N, Anker SD, Maisel A. Short-term mortality risk in emergency department acute heart failure. *Acad Emerg Med* 2011;18:947-58.
297. French D, Smollin C, Ruan W, Drasner K, Wu AHB. Partition constant and volume of distribution as predictors of clinical efficacy of lipid rescue for toxicological emergencies. *Clin Tox* 2011;49:801-9.
298. Wu AHB. Drug metabolizing enzymes activities versus genetic variances for drug of clinical pharmacogenomic relevance. *Clin Proteom* 2011,18:12-21.
299. Lung DD, Gerona RR, Wu AH, Smollin CG. Confirmed glyburide poisoning from ingestion of "street valium". *J Emerg Med* 2012;43:276-8.

300. Ruan W, French D, Wong A, Drasner K, Wu AHB. A mixed (long- and medium-chain) triglyceride lipid emulsion extracts local anesthetic from human serum in vitro more effectively than a long-chain emulsion. *Anesthesiol* 2012;116:334-9.
301. Wu AHB, Tabas JA, Vollert JO, Latuerback T, Mocker M. Results of novel cardiac biomarkers in Tako-Tsubo cardiomyopathy. *Int J Cardiol.* 2012;159:53-5.
302. Maisel A, Neath SX, Landsberg J, Mueller C, Nowak R, Peacock WF, Ponikowski P, Mockel M, Hogan C, Wu AHB, Richards M, Clopton P, Filippatos GS, Di Somma S, Anand I, Ng L, Daniels LB, Christenson R, Potocki M, McCord J, Terracciano G, Hartmann O, Bergmann A, Morgenthaler NG, Anker SD. Use of procalcitonin for the diagnosis of pneumonia in patients presenting with a chief complaint of dyspnoea: results from the BACH (Biomarkers in Acute Heart Failure) trial. *Eur J Heart Failure* 2012; 14:278-86.
303. Daniels LB, Clopton P, Potocki M, Mueller C, McCord J, Richards M, Hartmann O, Wu AHB, Nowak R, Peacock WF, Ponikowski P, Moeckel M, Hogan C, Filippatos GS, Di Somma S, Ander I, Ng L, Neath SN, Christenson R, Morgenthaler NG, Anker SD, Maisel AS. Influence of age, race, sex and body mass index on interpretation of midregional pro atrial natriuretic peptide for the diagnosis of acute heart failure: results from the BACH Multinational Study. 2011, *Eur J Heart Failure* 2012;14:22-31.
304. Lorizio W, Wu AHB, Beattie MS, Rugo H, Tchu S, Kerlikowske K, Cummings SR, Ziv E. Clinical and biomarker predictors of side effects from tamoxifen. *Breast Cancer Res Ther* 2012;132:1107-18.
305. Wu AHB, Lorizio W, Tchu S, Lynch K, Gerona R, Wuyang Ji, Ruan W, Ruddy KJ, Desantis SD, Burstein HJ, Ziv E. Estimation of tamoxifen metabolite concentrations in the blood of breast cancer patients through CYP2D6 genotype activity score. *Breast Cancer Res Treat* 2012;133:677-83.
306. Armenian P, Gerona RR, Blanc PD, Wu AHB, Mookherjee S. 5-Oxoprolinemia causing elevated anion gap metabolic acidosis in the setting of acetaminophen use. *Clin Toxicol* 2012;43:54-7.
307. Wu AHB. Biomarkers beyond the natriuretic peptides for chronic heart failure: galectin-3 and ST2. *eIFCC* 2012;23(3):epub.
308. Dempsey D, Meyers Oh, Fuentes-Afflick, Wu AHB, Jacob P, Benowitz N. Tobacco smoke exposure determined by plasma cotinine in infants and children attending urban hospital clinics. *Arch Pediatr* 2012, 166:851-6.
309. Ly BT, Thornton SL, Buono C, Stone JA, Wu AHB. False-positive phencyclidine immunoassay screen due to interference by tramadol and its metabolites. *Ann Emerg Med* 2012;59:545-7.
310. Wu AHB, Tabas J, Stein J, Potocki M, Mueller C, McCord J, Richards M, Hartmann O, Nowak R, Peacock WF, Ponikowski P, Moeckel M, Hogan C, Filippatos GS, Di Somma S, Anand I, Ng L, Neath SX, Christenson R, Morgenthaler RG, Anker SD, Maisel AS. The effect of diabetes on the diagnostic and prognostic performance of mid-region pro-adrenomedullin and mid-region pro-atrial natriuretic peptide in patients with acute dyspnea. An analysis from the Biomarkers from Acute Heart Failure (BACH) Study. *Biomarkers* 2012;17:490-7.



311. Wu AHB, Gerona R, Armenian P, French D, Petrie M, Lynch KL. Role of liquid chromatography-high-resolution mass spectrometry (LC-HR/MS) in clinical toxicology. *Clin Toxicol* 2012;50:733-42.
312. Gerona R, Wu AHB. Bath salts. *Clin Lab Med* 2012, 32:415-428.
313. Schreiber D, Todd J, Agbo C, Wu AHB. Ninety-minute rule out for acute myocardial infarction and 30-day risk stratification using a novel third generation high sensitivity troponin I assay. *Clin Biochem* 2012; 45:1295-301.
314. Wu AHB, Akhigbe P, Wians F. Long-term biological variation in cardiac troponin I. *Clin Biochem* 2012; 45:714-6.
315. Petrie MS, Lynch KL, Wu AHB, Steinhardt AA, Horowitz GL. Prescription compliance or illicit designer drug abuse? *Clin Chem* 2012,58:1631-33.
316. Thornton SL, Lo JCY, Clark, RF, Gerona R, Wu AHB. Simultaneous detection of multiple novel psychoactive substances in serum, urine and CSF in a patient with prolonged psychosis. *Clin Toxicol* 2012, 50:1165-8.
317. Cantrell L, Gerona G, Suchard J, Wu AHB. Stability of active ingredients in long-expired prescription medications. *Arch Intern Med* 2012, 172:1685-8.
318. Perera MA, Cavallari LH, Limdi NA, Gamazon ER, Konkashbaev A, Daneshjou R, Pluzhnikov A, Crawford DC, Wang J, Liu N, Tatonetti NJ, Bourgeois S, Takahashi H, Bradford Y, Burkely BM, Desnick RJ, Halperin JL, Khalifa SI, Langae TY, Lubitz SA, Nutscu EA, Oetjens M, Shahin MH, Shitalben RP, Tector M, Rieder MJ, Scott SA, Wu AHB, Burmester JK, Delouki P, Wagner MJ, Mushiroda T, Kubo M, Roden DM, Cox NJ, Altman RB, Klein TE, Nakamura Y, Johnson JA. A novel CYP2C SNP associated with warfarin dose in a large multicenter cohort of African Americans: the International Warfarin Pharmacogenetics Consortium (IWPC) genome wide association study. *Lancet* 2013;382(9894):790-6.
319. Moeckel M, Searle J, Hartmann O, Anker SD, Peacock WF, Wu AHB, Maisel A, on behalf of the BACH Writing Group. Mid-retional pro-adrenomedullin improves disposition strategies for patients with acute dyspnea: results from the BACH trial. *Emerg Med J* 2013;30:633-7.
320. Wu AHB. Recent advances in cardiac point-of-care diagnostics. *eIFCC* 2014, 25(2):40-7.
321. Wu AHB, Wians F Jr, Jaffe AS. Biological variation of galectin-3 and soluble ST2 for chronic heart failure: implication on interpretation of test results. *Am Heart J* 2013: 165:995-9.
322. Sporer KA, Solares M, Durant EJ, Wang W, Wu AHB, Rodriguez RM. Accuracy of the initial diagnosis among patients with an acutely altered mental status. *Emerg Med J* 2013;30:243-246
323. Wu AHB, French D. Implementation of liquid chromatography/mass spectrometry into the clinical laboratory. *Clin Chim Acta* 2013;420:4-10.
324. Maisel A, Mueller C, Neath SX, Christenson RH, Morgenthaler NG, Nowak RM, Vike G, Daniels LB, Hollander JE, Apple FS, Cannon C, Nagurney JT, Schreiber D, DeFilippi C, Hogan C, Diercks D, Stein J, Geadden G, Limkakeng AT, Anand I, Wu AHB, Papassotriou J, Hartman O, Ebmeyer S, Clopton P, Jaffe A, Peacock WF. Primary

- results of Copeptin Helps in the Early Detection of Patients with Acute Myocardial Infarction (CHOPIN) Trial. *J Am Coll Cardiol* 2013;62:150-60.
325. Wu AHB, Christenson RH. Analytical issues for use of cardiac troponin testing for risk stratification in primary care. *Clin Biochem* 2013, 46:969-78.
  326. Kim Y, Wu AHB. C3435T polymorphism of MDR1 gene with warfarin resistance. *Clin Chim Acta* 2013, 425:34-6.
  327. Petrie M, Lynch KL, Ekins S, Wu AHB, Krasowski MD. Cross-reactivity studies and predictive modeling of “bath salts” and other amphetamine-type stimulants with amphetamine screening immunoassays. *Clin Toxicol* 2013;51:83-91.
  328. Lung DD, Wu AHB, Gerona R. Cardiotoxicity in citalopram and olanzapine overdose. *J Emerg Med* 2013, 45:554-8.
  329. Armenian P, Mamantov TM, Tsutaoka BT, Gerona RRL, Silman EF, Wu AHB, Olson KR. Multiple MDMA (ecstasy) overdoses at a rave event: A case series. *J Inten Care Med* 2013;28:252-8.
  330. Smith A, Wu AHB, Lynch KL, Ko N, Grenache DG. Multi-wavelength spectrophotometric analysis for detection of xanthochromia in cerebrospinal fluid and accuracy for the diagnosis of subarachnoid hemorrhage. *Clin Chim Acta* 2013;424:231-6.
  331. Wu AHB. Genotype and phenotype accuracy for pharmacogenetic tests through proficiency survey testing. *Arch Pathol Lab Med* 2013,137:1232-6.
  332. Lung DD, Scott BJ, Gerona RR, Wu AHB. Prolonged ventilator failure and flaccid quadriplegia following ingestion of poison hemlock. *Muscle Nerve* 2013, 48:823-7.
  333. Markova S, Bendjilali N, Kobashigawa EA, Mefford J, Sodhi J, Hoa L, Halladay J, Rettie AE, Khojasteh C, McGlothlin D, Wu AHB, Hsueh WC, Witte JS, De Marco T, Schwartz JB, Kroetz DL. Association of CYP2C9\*2 with bosentan induced liver injury. *Clin Pharmacol Ther* 2013, 94:678-86.
  334. Wu AHB. Biological and analytical variation of clinical biomarker testing: implications for biomarker-guided therapy. *Curr Heart Fail Rep* 2013, DOI 10.1007/S11897-013-0156-6.
  335. Todd J, Simpson P, Estis J, Torres V, Wu AHB. Reference range and biological variation for interleukin (IL)-6, IL-17A and tissue necrosis factor alpha. *Cytokines* 2013;64:660-5.
  336. Wu AHB, Kearney T. Lack of impairment due to confirmed codeine use prior to a motor vehicle accident: role of pharmacogenomics. *J Foren Legal Med* 2013,20:1024-7.
  337. Lung DD, Wu AHB, Gerona R. Cardiotoxicity in citalopram and olanzapine overdose. *J Emerg Med* 2013,45:554-8.
  338. Ruddy KJ, Desantis SD, Gelman R, Wu AHB, Punglia RS, Mayer EL, Tolaney SM, Winer EP, Partridge AH, Burstein H. Personalized medicine in breast cancer: tamoxifen, endoxifen, and CYP2D6 in clinical practice. *Breast Cancer Clin Med* 2013,141:421-7.
  339. Richards M, Di Somma S, Mueller C, Nowak R, Peacock WF, Ponikowski P, Mockel M, Hogan C, Wu AH, Clopton P, Filippatos GS, Anand I, Ng L, Daniels LB,


- Neath SX, Shah K, Christenson R, Hartmann O, Anker SD, Maisel A. Atrial fibrillation impairs the diagnostic performance of cardiac natriuretic peptides in dyspneic patients: results from the BACH Study (Biomarkers in ACute Heart Failure). *JACC Heart Fail.* 2013 1(3):192-9.
340. O'Connor K, Chang AM, Wu AHB, Hollander JE. Myeloperoxidase and C-reactive protein in patients with cocaine-associated chest pain. *Am J Emerg Med* 2013,31:664-9.
341. Wang BT, Colby J, Wu AHB, Lynch KL. Cross-reactivity of acetyl fentanyl and risperidone with an automated urine fentanyl immunoassay. *J Anal Toxicol* 2014,38:672-5.
342. Neath SX, Jefferies JL, Berger JS, Wu AH, McConnell JP, Boone JL, McCullough PA, Jesse RL, Maisel AS. The current and future landscape of urinary thromboxane testing to evaluate atherothrombotic risk. *Rev Cardiovasc Med.* 2014; 15(2):119-30.
343. Wu AHB, Ruan W, Todd J, Lynch K. Biological variation of  $\beta$ -sitosterol, campesterol, and lathosterol as cholesterol synthesis and absorption biomarkers. *Clin Chim Acta* 2014;430:43-7.
344. Wu AHB. Biomarkers for cholesterol absorption and synthesis in hypercholesterolemic patients: role for therapeutic selection. *Clin Lab Med* 2014;34:157-66.
345. Roberts-Wilson TR, Kraft CS, French D, Ji W, Wu AHB, Tangpricha V, Fantz CR. Interpreting laboratory results in transgender patients on hormone therapy. *Am J Med* 2014;127:159-62.
346. Province MA, Goetz MP, Brauch H, Flockhart DA, Hebert JM, Whaley R, Suman VJ, Schroth W, Winter S, Zembutsu H, Mushiroda T, Newman WG, Lee MTM, Ambrosone C, Beckman MW, Choi JY, Dieudonne AS, Fasching PA, Ferraldeschi R, Gong L, Haschke-Bechler E, Howell A, Jordan LB, Hamann U, Kiyotani K, Krippel P, Lambrechts D, Latif A, Lorzio W, Neven P, Nguyen AT, Park BW, Purdie CA, Quinlin P, Renner W, Schmidt M, Schwab M, Shin JG, Stingl JC, Wegman P, Wingren S, Wu AHB, Ziv E, Zirpoli G, Thompson AM, Weinshilboum RM, Eichelbaum E, Ingle JN, Klein TE. *CYP2D6* Genotype and Adjuvant Tamoxifen: Meta-Analysis of Heterogeneous Study Populations *Clin Pharmacol Ther* 2014,95:216-27.
347. Lipinski MJ, Baker NC, Escárcega RO, Torguson R, Chen F, Aldous SJ, Christ M, Collinson PO, Goodacre SW, Mair J, Inoue K, Lotze U, Sebbane M, Cristol JP, Freund Y, Chenevier-Gobeaux C, Meune C, Eggers KM, Pracon R, Schreiber DH, Wu AH, Ordoñez-Llanos J, Jaffe AS, Twerenbold R, Mueller C, Waksman R. Comparison of conventional and high-sensitivity troponin in patients with chest pain: a collaborative meta-analysis. *Am Heart J.* 2015 Jan; 169(1):6-16.e6.
348. Storrow A B, Christenson RH, Nowak RM, Diercks DB, Singer AJ, Wu AHB, Kulstad E, LoVecchio F, Fromm C, Headden G, Potis T, Hogan CJ, Schrock JW, Zelinsk DPi, Greenberg MR, Ritchie JC, Chamberlin JS, Bray KR, Rhodes DW, Trainor D, Holmes D, Southwick PC. Diagnostic performance of cardiac troponin I for early rule in

- and rule out of acute myocardial infarction: results of a prospective multicenter trial. *Clin Biochem* 2015;48:260-7.
349. Selden N, Shugarts S, Wu A, Lung D. Near-fatal, antihypertensive medication overdose due to post-operative gastric ileus. *Clin Pharmacol Ther* 2014;39:695-71.
  350. Finlay J, Wu AHB. Biological variation of immunoglobulin heavy-light chain pairs in serum. *Clin Chim Acta* 2014, 436:68-71.
  351. Heath DD, Flatt SW, Wu AHB, Pruitt MA, Rock CL. Evaluation of tamoxifen and metabolites by LC-MS/MS and HPLC methods. *Br J Biomed Sci* 2014;71:33-9.
  352. Storrow A B, Nowak RM, Diercks DB, Singer AJ, Wu AHB, Kulstad E, LoVecchio F, Fromm C, Headden G, Potis T, Hogan CJ, Schrock JW, Zelinski DP, Greenberg MR, Christenson RH, Ritchie JC, Chamberlin JS, Bray KR, Rhodes DW, Trainor D, Southwick PC. Absolute and relative changes (delta) in troponin I for early diagnosis of myocardial infarction: results of a prospective multicenter trial. *Clin Biochem* 2014, DOI: 10.1016/j.clinbiochem.2014.09.012
  353. Mishra RK, Beatty AL, Jaganath R, Regan M, Wu AHB, Whooley MA. B-type natriuretic peptides for the prediction of adverse cardiovascular events in patients with stable coronary heart disease: the Heart and Soul Study. *J Am Heart Assoc* 2014, 3:e000907.
  354. Wang BZ, Colby J, Wu AHB, Lynch K. Cross-reactivity of acetyl fentanyl and risperidone with a fentanyl immunoassay. *J Anal Toxicol* 2015;38:672-5.
  355. Wu AHB. Analytical validation of novel cardiac biomarkers used in clinical trials. *Am Heart J* 2015, 169:674-83.
  356. Oh SS, Galanter J, Thakur N, Pino-Yanaes M, Barcelo NE, White MJ, deBruin DM, Greenblatt RM, Bibbins-Domingo K, Wu AHB, Borrells LN, Gunter C, Powe NR, Burchard EG. Diversity in clinical and biomedical research: a promise yet to be fulfilled. *Plos Med* 2016, 12(12): e1001918. doi:10.1371/journal.pmed.1001918.
  357. Wu AHB, Hamilton R, Middleberg R, Kacinko S, Kearney T. Investigation of postmortem absorption and redistribution after the application of a fentanyl patch. *J Foren Sci* 2015;60:532-5.
  358. Wu AHB, Lynch K. Therapeutic drug monitoring to support clinical pharmacogenomics. In preparation.
  359. Wu AHB, Yang HS, Thoren K. Biological variation of serum osmolality and the osmolal gap. *Clin Biochem* 2014, 47:130-1.
  360. Madasamy S, Chaudhuri V, Kong R, Adams C, Knaak T, Ruan W, Wu AHB, Bigos M, Amento E. Plaque array method and proteomics-based identification of biomarkers from Alzheimer's disease serum. *Clin Chim Acta* 2015, 441:79-85.
  361. Wu AHB, van Wijk XMR. A new ultra-high sensitivity troponin I assay for chest pain patients with no evidence of troponin I using a conventional assay. *Clin Biochem* 2015, 48:358-9.
  362. Petterman C, Wu A, Reiner-Benaim A, Batty DS, Sanz I, Oates J, Jakobi K, Petri M, Safer P, Gerwien R, Sorek R, Blumenstein Y, Cohen IR. SLE-key rule-out serologic test for

- excluding the diagnosis of systemic lupus erythematosus: developing the ImmunArrayiCHIP. *J Immunol Methods*. 2016 Feb;429:1-6. doi: 10.1016/j.jim.2015.12.003. Epub 2015 Dec 8.
363. Aw TC, Wijk XMR, Wu AHB, Jaffe A. Release of cardiac troponin using a high sensitivity assay after exercise: type 2 acute myocardial infarction? *Clin Chim Acta* 2015, 446:6-8.
364. Maxwell NM, NevinRL, Stahl S, Block J, Shugarts S, Wu AHB, Dominy S, Solano Blanco MA, Kappelman-Culber S, Lee-Messer C, Maldonado J, Maxwell AJ. Prolonged neuropsychiatric effects following management of chloroquine intoxication with psychotropic polypharmacy. *Clin Case Reports* 2015;3:379-87.
365. Wu AHB, White M, Burchard E. The Hawaii clopidogrel lawsuit: the possible effect on clinical laboratory testing. *Person Med* 2015;12:179-81.
366. Shah KS, Marston NA, Mueller C, Neath SX, Christenson R, McCord J, Nowak RM, Vilke GM, Daniels LB, Hollander J, Apple F, Cannon CM, Nagurney J, Schreiber D, DeFillippi C, Hogan C, Diercks D, Limkakeng A, Anand IS, Wu AHB, Clopton P, Jaffe AS, Peacock WF, Maisel A. Midregional pro-adrenomedullin predicts mortality and major adverse cardiac events in patients presenting with chest pain: results from the CHOPIN Trial. *Acad Emerg Med* 2015;22:554-63.
367. Secemsky EA, Scherzer R, Nitta E, Wu AHB, Lange DC, Deeks SG, Martin JN, Snider J, Ganz P, Hsue PY. Biomarkers of cardiovascular stress are associated with structural heart disease and mortality in HIV-infected individuals. *J Am Coll Cardiol Heart Fail* 2015;3(8):591-9.
368. Colby J, Wu AHB, Lynch KL. Analysis of codeine positivity in urine of pain management patients. *J Anal Toxicol* 2015;39:407-10.
369. Yang HE, Wu AHB, Johnson-Davis KL, et al. Development and validation of an LC-MS/MS sulfonylurea assay for hypoglycemia cases in the emergency department. *Clin Chim Acta* 2016;454:130-4.
370. Sandoval Y, Herzog CA, Love SA, Cao J, Hu Y, Wu AHB, Gilbertson D, Brunelli SM, Young A, Ler R, Apple FS. Prognostic value of serial changes in high-sensitivity cardiac troponin I and T over 3 months using reference change values in hemodialysis patients. *Clin Chem* 2016;62:631-8.
371. Marston N, Maisel AS, Marston N, Shah KS, Mueller C, Neath SX, Christenson R, McCord J, Nowak RM, Vilke G, Daniels L, Hollander J, Apple F, Cannon C, Nagurney J, Schreiber D, deFillippi C, Hogan C, Diercks D, Limkakeng A, Anand I, Wu AHB, Clopton P, Jaffe AS, Peacock WF. Serial sampling of copeptin levels improves diagnosis and risk stratification in patients presenting with chest pain: Results from the CHOPIN Trial. *Emerg Med J* 2016;33(1):23-9. doi: 10.1136/emermed-2015-204692.
372. Vo K, van Wijk X, Lynch KL, Wu AHB, Smollin CS. Counterfeit Norco poisoning outbreak — San Francisco and Bay Area, California, 2016. *MMWR* 2016;65.
373. Korley FK, Aw Diaz-Arrastia R, Wu AHB, Yue JK, Manley GT, Sair H, Van Eyk J, Everett A, Okonkwo DO, Valadka AB, Gordon WA, Maas AIR. Circulating brain derived neurotrophic factor (BDNF) has diagnostic and prognostic value in traumatic brain injury. *J Neurotrauma*. 2016;33(2):215-25.

374. Wu AHB, Colby J. High-resolution mass spectrometry for untargeted drug screening. *Meth Mol Biol* 2016;1383:153-66.
375. Jordan JA, Plantier JC, Templeton K, Wu AHB,. Multi-site evaluation of the Xpert HIV-1 viral load assay. *J Clin Virol* 2016;80:27-32.
376. Thoren KL, Colby JM, Shugarts B, Wu AHB, Lynch KL. Comparison of information-dependent acquisition on a tandem quadrupole TOF vs a triple quadrupole linear ion trap mass spectrometer for broad-spectrum drug screening. *Clin Chem* 2016, 62:170-8.
377. Madasamy S, Shivasubramani U, Villaneuva J, Bigos B, Amento EP, Wu AHB. Non-enzymatic mechanism of statins in modulating cholesterol particles formation. *Am J Cardiol* 2016;118:7-93.
378. Wu AHB. The importance of promoting the value of precision medicine to the public. The power of storytelling. *Exp Rev Precision Med Drug Develop* 2016, 1:233-4.
379. Vo KT, van Wijk XMR, Wu AHB, Lynch KL, Ho RY. Synthetic agents off the dark net: a case of U-47700 and phenazepam abuse. *CLin Toxicol (Phila)*, 2017;55:71-2.
380. Meijers WC, van der Velde AR, Muller Kobold AC, Dijk-Brouwer J, Wu AH, Jaffe AS, de Boer RA. Variability of biomarkers in patients with chronic heart failure and healthy controls. *Eur J Heart Fail* 2017;18:357-65.
381. Yang HS, Wu AHB, Lynch KL. Development and validation of a novel LC-MS/MS opioid confirmation assay: evaluation of  $\beta$ -glucuronidase enzymes and sample cleanup methods. *J Anal Toxicol* 2016 40(5):323-9. doi: 10.1093/jat/bkw026.
382. Beri N, Marston NA, Daniels LB, Nowak RM, Schreiber D, Mueller C, Jaffe A, Diercks DB, Wetterstein N, DeFilippi C, Peacock WF, Limkakeng AT, Anand I, McCord J, Hollander JE, Wu AHB, Apple FS, Nagurny JT, Berardi C, Canon CM, Clopton P, Neath SX, Christenson RH, Hogan C, Vilke G, Maisel A. Necessity of hospitalization and stress testing in “low risk” chest pain patients: results from the CHOPIN trial. *Am J Emerg Med* 2017;35:274-80.
383. Van Wijk XMR, Magee CG, Wu AHB, Tana MM, Lynch KL. A comparison of methods for evaluation of a case of suspected macro aspartate aminotransferase. *Clin Chim Acta* 2016;463:1-3. doi: 10.1016/j.cca.2016.10.011
384. Surofchy D, Oh SS, Xian P, Li M, Guo S, Desai T, Guglielmo BJ, Giacomini K, Long-Boyle J, Wu AHB, Burchard E. The effect of personalized pharmacogenetics testing on the effects of pharmacy student perceptions of knowledge and attitudes towards precision medicine. *J Pharm Educ* 2017;8(1): Article 2. <http://pubs.lib.umn.edu/innovations/vol8/iss1/2>.
385. Li K, Van Wijk X, Hayashi S, Lynch K, Wu AH, Smollin C. Anticholinergic toxicity associated with ingestion of water containing bean extract. *Clin Toxicol* 2017,55(7):687-8
386. Mishra RK, Judson G, Meyer CS, Christenson RH, DeFilippi C, Wu AHB, Whooley MA. The association of five-year change in N-terminal fragment of the prohormone brain-type natriuretic peptide (NT-proBNP) with subsequent heart failure and death in patients with stable coronary artery disease: The Heart and Soul Study. *Cardiol* 2017, 137:201-6.

387. De Vries Schultink AHM, Alexi X, van Werkhoven E, Madlensky L, Natarajan L, Flatt SW, Zwart W, Linn SC, Parker BA, Wu AHB, Pierce jP, Huitema ADR, Beijnen JH. An antiestrogen activity score (ASS) for tamoxifen, which takes into account the antiestrogenic activity and concentration of tamoxifen and three of its metabolites, was developed and associated with breast cancer outcomes. *Breast Cancer Res* 2017;161(3):567-74.
388. Riley ED, Hsue PY, Vittinghoo E, Wu AHB, Coffin P, Moore PK, Lynch KL. Higher prevalence of detectable troponin I among cocaine users without known cardiovascular disease. *Drug Alcohol Depend* 2017;172:88-93.
389. Wu AHB, Apple FS, Love SA, Koch D, Myers GL, Christenson RH, on behalf of the AACC's Biomarkers of Acute Cardiovascular Disease Division. Creation of a Universal Sample Bank for Determining the 99<sup>th</sup> Percentile for Cardiac Troponin Assays. *J Appl Lab Med* 2017;1:711-719.
390. Burnett RW, Ladenson JE, Wu AHB, Moore RE. Pioneers in clinical chemistry: George N. Bowers, Jr., M.D. and Robert B. McComb, Ph.D. *J Appl Lab Med* 2017;1:758-62
391. Baratelink IH, Prideaux B, Krings G, Wilmes L, Lee PRE, Hann B, Coppe JP, Swigart-Brown L, Jones EF, Magnitsky S, Keizer R, Esserman L, Ruan W, Wu A, Yee D, Dartois V, Wolf D, Savic R, van't Veer L. Non-homogeneous drug penetration of veliparib measured in triple negative breast tumors. *Clin Pharmacol Therap* 2016;99:S11.
392. Kyle P, Fuller DC, Garg U, Hammett-Stabler CA, Hoess E, Johnson-Davis K, Kapur BM, Langman LJ, LeGatt DF, Loughmiller D, Pesce A, Sadek W, Smith MP, Watson ID, Wolf CE, Wu A, Zhang YV. Toxicology and drug testing in the medical lab. *Clinical Laboratory Standards Institute* 2017;C52.
393. Miao J, Friedman E, Wu AHB, Todd JA, Estis J, Xu X, Nolan N, Bishop JJ, Lenihan DR. Clinical utility of single molecule counting technology for quantification of KIM-1 in patients with heart failure and chronic kidney disease. *Clin Biochem* 2017;50:889-95.
394. Thaker M, Angira F, Pattanapanyasat K, Wu AHB, O'Gorman M, Zeng H, Qu C, Mahajan B, Sukapirom K, Chen D, Hao Y, Gong Y, DE Arruda-Indig M, Graminske S, Orta D, d'Empaire N, Lu B, Omaza-Zapaa I, Zeh C. CD4 lymphocyte enumeration and hemoglobin assessment for priority decisions: a multisite evaluation of the BD FACSPresto system. *Open AIDS J* 2017;11:76-90.
395. Vo KT, Horng H Li K, Ho RY, Wu AHB, Lynch KL, Smollin CG. Cannabis intoxication case series: the dangers of edibles containing tetrahydrocannabinol. 2017; <https://doi.org/10.1016/j.annemergmed.2017.09.008>
396. Kavsak PA, Jaffe AS, Green D, Christenson R, Wu AHB. Total analytic error for low cardiac troponin concentrations (<10 ng/L) by use of a high-sensitivity cardiac troponin assay. *Clin Chem* 2017;63:1043-5.
397. Thoren K, Basi B, Delgado J, Wu AHB, Lynch KL. Quantitation of infliximab and detection of anti-drug antibodies in serum using surface plasmon resonance. *J Appl Lab Med*. 2017. DOI: 10.1373/jalm.2017.024380.

398. Van Wijk XMR, Vittinghoff E, Wu AHB, Lynch KL, Riley ED. Cocaine use is associated with elevated ST2 concentrations in the absence of known clinical cardiovascular disease. *Clin Biochem* 2017;50:791-3.
399. Beunders R, Struck J, Wu AHB, Mehta RL, Koyner JL, Di Somma S, Maisel As, Pickkers P. Pro-Enkephalin (PENK) as a novel biomarker for kidney function. 2017; 2:400-12.
400. Wu AHB. Release of cardiac troponin from healthy and damaged myocardium. *Front Lab Med* 2017;1:144-50.
401. McHugh MP, Wu AHB, Pawlotsky JM, Chevaliez S, Hallin M, Templeton KE. Multicentre preclinical evaluation of the Cepheid Xpert hepatitis C virus (HCV) viral load assay. 2017, DOI: 10.1128/JCM.02460-16.
402. Li P, Enea NS, Zuk R, Tan H, Wu AHB, Jaffe AS. Performance characteristics of a high-sensitivity cardiac troponin assay using plasma and whole blood samples. *Clin Biochem* 2017;50:1249-52.
403. Estis J, Wu AHB, Todd J, Bishop J, Kavsak PA. Comprehensive age and sex 99<sup>th</sup> percentile reference intervals for a high-sensitivity cardiac troponin I assay. *Clin Chem* 2017, 62: DOI: 10.1373/clinchem.2017.276972
404. Rodda L, Volk J, Moffatt E, Williams CM, Lynch K, Wu AHB. Intraosseous fluid as alternative biological specimen in postmortem toxicology. *J Anal Toxicol* 2017, doi.org/10.1093/jat/bkx096
405. Wu AHB, Christenson RH, Greene DN, Jaffe AS, Kavsak PA, Ordonez-Llanos J, Apple FS. Clinical laboratory practice recommendations for use of cardiac troponin in acute coronary syndrome: expert opinion from the Academy of the American Association for Clinical Chemistry and the Task Force on Clinical Applications of Cardio Bio-markers of the International Federation of Clinical Chemistry and Laboratory Medicine. *Clin Chem* 2018;64(4):645-655.
406. Madasamy S, Wu AHB, Evidence for role of lipid-lowering drugs in modulating folding and fusion of cholesterol particles. *Nature Nanotech*, submitted, 2016.
407. Madasamy S, Liu D, Lundry J, Alderete B, Kong R, Robinson JP, Wu AHB. Differential effects of lipid-lowering drugs in modulating morphology of cholesterol particles. *J Vis Exp*. 2017 Nov 10;(129). doi: 10.3791/56596.
408. Clancy CJ, Pappas PG, Vazquez J, Judson M, Kontoyiannis DP, Thompson GR, Garey KW, Reboli A, Greenberg R, Apewokin S, Lyons M, Ostrosky-Zeichner L, Wu A, Tobin E, Nguyen MH, Caliendo AM. Detecting infections rapidly and easily for Candidemia Trial-2 (DIRECT2): a prospective, multicenter study of the T2Candida Panel. *Clin Infect Dis*. 2018;66(11):1678-86.
409. Madasamy S, Liu D, Lundry J, Alderete B, Kong R, Robinson JP, Wu AHB, Amento EP. Differential effects of lipid-lowering drugs in modulating phenotypes of cholesterol particles. *J Vis Exp* 2017; (129): 56596. doi: [10.3791/56596](https://doi.org/10.3791/56596)
410.  Beri N, Daniels LB, Jaffe A, Mueller C, Anand I, Peacock WF, Hollander JE, DeFilippi C, Schreiber D, McCord J, Limkakeng AT, Wu AHB, Apple FS, Diercks DB, Nagurney JT, Nowak RM, Cannon CM, Clopton P, Neath S-X, Christenson RH, Hogan C, Vilke G, Maisel A. Copeptin to rule out myocardial infarction in Blacks versus



Caucasians. *Eur Heart J. Acute Cardiovascul Care*, 2018; doi:  
[10.1177/2048872618772500](https://doi.org/10.1177/2048872618772500)

411. Trivedi NN, Brown JK, Rubenstein T, Rostykus AD, Fish A, Yu Heng, Carbonell L, Juang A, Kamer S, Patel B, Sidhu M, Vuong D, Wang S, Beggs M, Wu AHB. Analytical validation of a novel multi-analytes plasma test for lung nodule characterization. *Biom Res Rev* 2018;2(3):1-10, doi: 10.15761/BRR.10000123
412. Trivedi NN, Arjomandi M, Brown JK, Rubenstein T, Rostykus AD, Esposito S, Axler E, Beggs M, Heng Y, Carbonell L, Juang A, Kamer S, Patel B, Wang S, Fish AL, Haddad Z, Wu AHB. Risk assessment for indeterminate pulmonary nodules using a novel, plasma protein based biomarker array. *Biomed Res Clin Pract* 2018,3(4): 1-8 doi: 10.15761/BRCP.1000173
413. Arens A, Vo K, Van Wijk X, Lynch K, Wu AHB, Lemos N, Smollin C. Counterfeit ‘Xanax’: a case series from San Francisco. 2016, in preparation.
414. Moore PK, Lynch KL, Wu AHB, Ma Y, Scherzer R, Weigel B, Riley ED, Hsue PY. Cross-sectional evaluation of cardiac troponin I in patients with recent cocaine and amphetamine use. *Heart* 2017, submitted.
415. Morosyuk S, Berube J, Christenson R, Wu AH, Uettwiller-Geiger D, Palicka V, Prusa R, Zima T, Petersmann A, Plokhoy E, Stankovic AK. Improvement of therapeutic drug stability in plasma samples collected in BD Vacutainer Barricor blood collection tubes with novel mechanical separator barrier. *Ther Drug Monit* In preparation, 2017.
416. Xie Y, Hitzeman TC, Zadikany RH, Nikolova A, Baum R, Xu B, Agvanian S, Melmed GY, Geft DR, Chang DH, Moriguchi JD, Hage A, Azarbal B, Czer LS, Kittleson MM, Patel JK, Wu AH, Kobashigawa JA, Hamilton M, Hong TT, Shaw RM. Plasma based cBIN1 score (CS) identifies HFrfEF and can predict cardiac hospitalization. 2017, in preparation.
417. Rosenbaum MW, Flood JG, Melanson SEF, Baumann NA, Marzinke MA, Rai AJ, Hayden J, Wu AHB, Lador M, Lifshitz MS, Scott M, Peck Palmer OM, Bowen R, Babic N, Sobhani K, Giacherio D, Bocsi G, Herman DS, Wang P, Toffaletti J, Handel E, Kelly KA, Albeiroti S, Wang S, Zimmer Z, Driver B, Yi X, Wilburn C, Lewandrowski KB. Quality control practices for chemistry and immunochemistry in a cohort of 21 large academic medical centers. In preparation, 2017.
418. Wu AHB. Is there a continual role for serum creatine kinase and myoglobin testing in the era of high sensitivity troponin assays? *Front Lab Med* 2018, submitted.
419. Van Wijk XMR, Yun C, Houghfar S, Arens A, Lung D, Wu AHB, Lynch KL. A liquid-chromatography high-resolution mass spectrometry method for non-FDA approved benzodiazepines. *J Anal Toxicol* accepted, 2018.
420. Moore PK, Lynch KL, Wu AHB, Ma Y, Scherzer R, Weigel B, Riley ED, Hsue PY. Cross-sectional evaluation of cardiac biomarkers in patients with recent cocaine and amphetamine use. *Am Heart J* 2018, in preparation.
421. Lee S, Ong CM, Wu AHB. Narrowed reference intervals for complete blood count in a multiethnic population. In preparation, 2018.

422. Wu AHB, Ghosh R, Ong CM, French D. Serum 25-hydroxyvitamin D concentrations from high risk groups for deficiency. *J Appl Lab Med* 2018, in preparation.
423. Wu AHB. Wearable clinical laboratory testing devices for emergency and critical care laboratory testing. *J Appl Lab Med* 2019, in preparation.
424. Aoullay Z, van Wijk XM, Yanhui M, Lynch KL, Wu AHB. Development and validation of a liquid chromatography-tandem mass spectrometry (LC-MS/MS) assay for simultaneous quantification of irinotecan and its principal metabolites in human plasma. 2019, in preparation.
425. Badea A, Ghosh R, Wu AHB. No cross reactivity of tianeptine to tricyclic antidepressant assays. *J Anal Toxicol* 2019, in preparation.

### Patents

1. Armstrong EG, Petry C, Wu AHB, Wagner G. Reflex algorithm for early and cost effective diagnosis of myocardial infarction suitable for automated diagnostic platforms. U.S. Patent 6,099,469, 2000.
2. Chapman-Montgomery ES, Okrongly D, Ahnardi CE, Wu A, Gervas An. Methods for monitoring patients for efficacy of an antiplatelet therapy regimen. U.S. Patent 7,723,064, 2010.
3. Goix PJ, Puskas R, Todd J, Livingston RA, Held D, Wu AHB. Highly Sensitive System and Methods for Analysis of Troponin, U.S. Patent. 7,838,250. 2010.

### NON-PEER REVIEWED PUBLICATIONS

#### LETTERS, NOTES

1. McComb RB, Wu AHB, Schoppman A, Inman S. User experience of the Roche Cobas Bio. *Clin Instrum System* 1981;2(5):4-5.
2. Wu AHB, Rotunno T, Malmstadt HV. Microcomputer-controlled photodiode array spectrophotometric titrator. *Amer Lab* 1982;13:16-34, and *Int Lab* 1982;12:16-28.
3. Wu AHB, Ohneck J, Klaus E, McComb RB. A washer-dryer system for cuvette rotors used in the Cobas-Bio Centrifugal Analyzer [Letter]. *Clin Chem* 1982;28:2188-9.
4. Wu AHB, McComb RB. Permanent vs. disposable rotors for centrifugal analyzers [Letter]. *Clin Chem* 1983;29:990-1.
5. Wu AHB. Current methods and limitations for fractionating creatine kinase isoenzymes. *Clin Lab* 1984;8:203-17.
6. Wu AHB. CK-MB assay methods. A comparison. *Lab Man* 1985;23(1):44-50.
7. Wu AHB. Support researchers. *Clin Chem News* 1985;11(12):4.
8. Wu AHB. Job market for clinical chemists is still strong. *Clin Chem News* 1987;13(5):5.
9. Wu AHB, Brockie R. Creatine kinase isoforms in acute myocardial infarction. College of American Pathologists, "Check Sample Program," in *Clin Chem* 1987;87-8 ((CC-186).
10. Wu AHB. User experience, The Helena Rep. *Clin Instrum Systems* 1988;10(1):5-6.
11. Wu AHB. Analysis of creatine kinase isoenzymes and isoforms. *Clin Lab* 1989;3(3):155-63.

12. Wu AHB. Introduction to Hypertension: Pathophysiology and Control. The Proceedings of the 14th Annual A.O. Beckman Conference. Clin Chem 1991;37:1809-10.
13. Wu AHB. Methods for creatine kinase isoform analysis. Clin Chem News 1992;17(6):19-20.
14. Wu AHB. Clinical Chemistry Questions and Answers: Fetal lung maturity assays. JIFCC 1993;5:154.
15. Apple FS, Wu AHB. Cardiac markers poster. Clin Chem News 1993;19(4):8.
16. Wu AHB. Clinical Chemistry Questions and Answers: Bedside drug testing. JIFCC 1994;6:14.
17. Wu AHB, Apple FS, Valdes R Jr. Cardiac troponin-T and diagnostic test evaluation. [Letter]. Clin Chem 1995;41:634-6.
18. Wu AHB. Cardiac troponin I: a tool for the times? Behring Mon 1996;13(1):1-6.
19. Wu AHB. New strategies, tools emerge for drugs of abuse. Advance Lab Med 1996;8(8):14-19.
20. Wu AHB, Jesse RL. Triaging the chest pain patient. Clin Lab News 1996;22:poster insert.
21. Wu AHB. Clinical Chemistry Questions and Answers: workstation consolidation. JIFCC 1996;9:170.
22. Wu AHB. A review on the methods and interpretation of alcohol (ethanol) measurements. MRO Update 1997;March:6-14.
23. Mascotti K, Wu AHB. Clinical Chemistry Questions and Answers: unbundling the chemistry profile. JIFCC 1997, 9(1):36.
24. Wu AHB. Detecting myocardial injury. Advance 1997;6:82-5.
25. Wu AHB. Impact of a high precision prostate specific antigen (PSA) assay on management of adenocarcinoma of the prostate: a case report. Bayer Internet 1998 ([http://www.bayerdiag/whats\\_new/library/on-line/immuno/psa.html](http://www.bayerdiag/whats_new/library/on-line/immuno/psa.html)).
26. Schwartz JG, Wu AHB. Questions and answers on diagnosis of myocardial infarction. CAP Today 1990;4(7):33-4.
27. Wu AHB, Rymut K. The adulteration of urine drug testing results with "Klear." Ther Drug Monit Clin Tox Newsletter 1997, 12(4):1-2.
28. Wu AHB. Cardiospecificity of biochemical markers in acute coronary syndromes. Intensivmed 1998;35:165-6.
29. Wu AHB. The value of cardiac markers for risk stratification in patients with acute coronary syndromes. Clin Lab News 1998,24(6):12-6.
30. Wu AHB. Clinical Chemistry Questions and Answers: Improving the diagnostic accuracy of PSA. JIFCC 1998;10:81.
31. Kidwell DA, Smith FP, Crouch D, Wu AHB. Commentary on minimal standards for the performance and interpretation of toxicology tests in legal proceedings. J Foren Sci 2000;45:237-9.
32. Bogusz MJ, Crouch D, Wu AHB. Further commentary. J Foren Sci 2000;45:1659-60.
33. Wu AHB. Clinical utility of cardiac troponin in acute coronary syndromes. Proceedings of the DPC Symposia and meeting in the Benelux, 1999.

34. Makowski GS, Hopfer SM, Tsongalis GJ, Wu AHB. Changes in academic productivity: implications for clinical laboratory research and development. [Letter]. Clin Chem 2000;46:303-5.
35. Wu AHB. Experience for police drug ID takes hit. Recognizing toluene not enough. The Forensic Panel, 2001; [www.forensicpanel.com](http://www.forensicpanel.com).
36. Wu AHB. B-type natriuretic peptide and its clinical utility in patients with heart failure. Med Lab Observer 2001;33(10):10-14.
37. Wu AHB. Point-of-care testing for cardiac markers: has the time come? Point of Care. 2002, 1:39-41.
38. Wu AHB. Cardiac markers: cost effective triage for myocardial infarction admission and therapy. Med Lab Observer 2002;34(6):36-40.
39. Wu AHB. Laboratory markers of CHF. Advance 2002;11(4):54-60.
40. Wu AHB, Valdes R Jr, Hawker CD. Guidelines and recommendations in laboratory medicine [letter]. Clin Chem 2002, 48:1135-6.
41. Wu AHB, Apple FS. Reporting of cardiac troponin concentration [letter]. Clin Chem 2002; 48:2077-82.
42. Wu AHB. The ischemia-modified albumin biomarker for myocardial ischemia. Med Lab Observer 2003;35(6):36-40.
43. Wu AHB. The role of cardiac troponin in the recent redefinition of acute myocardial infarction. Clin Lab Sci 2004, 17:50-2.
44. Wu AHB. Clinical laboratory diagnosis of stroke. Life Sci BTR 2004, 1(2):30-1.
45. Wu AHB, Apple FS, Jaffe A, Galvani M. British Cardiac Society's troponin cutoff concentration for myocardial infarction: "back to the future?" [eLetter]. Heart 2004. <http://heart.bmjournals.com/cgi/eletters/90/6/603>.
46. Wu AHB. Stroke diagnosis. ASCP Check Sample Program, 2005, 45(8):113-26.
47. Wu AHB. Point-of-care testing for cardiac markers at the bedside. Bus Brief Emerg Med Review 2005, 42-3. <http://www.touchbriefings.com/cdps/cditem.cfm?NID=1334&CID=5&CFID=2346301&CFTOKEN=9#Contents>
48. Joelson DW, Wu AHB. BNP for screening and monitoring of heart failure. ASCP Check Sample Program, 2006, 46(5):55-66.
49. Wu AHB. Update on the analytical aspects and clinical applications of natriuretic peptides. Advance 2006, 15(1):34-8.
50. Wu AHB, Gross S. Response to Tips from the clinical experts. MLO 2006, 38(2):6-8.
51. Wu AHB. Toxicology testing in the emergency department: meeting changing needs. Clin Lab News 2006;32(9):14-6.
52. Wang P, Haller CA, Wu AHB. Crystal methamphetamine: abuse, toxicity and laboratory detection. Clin Foren Toxicol Newsletter, AACC Press, 2007.
53. Bailey H, Wu AHB. Bright green serum. Images in clinical medicine. N Engl J Med 2007;356:e10.
54. Wu AHB, Guglielmo J, Hamill T, Haller C. Clinical laboratory needs for pharmacogenomic testing [Letter]. Ann Intern Med 2007, online. <http://www.annals.org/cgi/eletters/145/10/749>

55. Wu AHB. Novel cardiac markers: beyond troponin and the natriuretic peptides. *Advance* 2008;20(2):38-40.
56. Wu AHB. The emergence of pharmacogenomics testing in the clinical laboratory. *Advance* 2008, 17(7):50-53.
57. Wu AHB. Current and future biomarkers of human cardiac disease. Proceedings of the American College of Veterinary Internal Medicine, San Antonio, TX, 2008.
58. Wu A. Integrated Biomarkers in Cardiovascular Disease – Third International Symposium. Conference Report. *IDrugs* 2008;11:636-8.
59. Wu AHB. FDA issues update on genetic testing and antiepileptics. *Clin Foren Toxicol News* 2009 (3):8.
60. Maisel A, Peacock WF, Wu A. A practical approach for the use of biomarkers in heart failure. *The Medical Roundtable*, 2011;4(2):208-14.
61. Wu AHB. Review of: Alcohol and its biomarkers. *J Foren Sci* 2017;62:276.

#### **INVITED EDITORIALS AND OPINIONS:**

1. Wu AHB. Increased troponin in patients with sepsis and septic shock: myocardial necrosis or reversible myocardial depression. [Editorial]. *Inten Care Med* 2001;27:959-60.
2. Wu AHB, Jialal I. How Specific is Cardiac Troponin? [Editorial]. *Am J Clin Pathol* 2000; 114:509-11.
3. Apple FS, Wu AHB. Myocardial infarction redefined: role of cardiac troponin testing. [Editorial]. *Chem Chem* 2001; 47:377-79.
4. Wu AHB. Cardiac troponin: friend of the cardiac physician. Foe to the cardiac patient? [Editorial]. *Circulation* 2006, 114:1673-74.
5. Thompson PD, Apple FS, Wu AHB. Marathoner's heart. [Editorial]. *Circulation* 2006, 114:2306-8.
6. Wu AHB. Warfarin pharmacogenomic testing platforms [Editorial]. *Pharmacogen* 2008;9:1002-3.
7. Wu AHB. Etiologies of troponin elevation in critically ill patients with gastrointestinal bleeding. [Editorial] *Crit Care Med* 2009;37:347-8.
8. Wu AHB. Gender-specific decision limits for cardiac troponin for risk stratification? [Editorial] *Anesth Analg* 2009, 108:686-8.
9. Wu A. Novel biomarkers of cardiovascular disease: myeloperoxidase for acute and/or chronic heart failure? [Editorial] *Clin Chem* 2009, 55:12-14.
10. Wu AHB. Pharmacogenomic testing for warfarin dosing: we are ready now. [Editorial] *Exp Rev Cardiovasc Ther* 2009;12:1483-5.
11. Wu AHB. Limitations of point-of-care testing in the ED or ICU: a role for regional centralized toxicology laboratories [Opinion]. *Clin Pharmacol Therap* 2010;88:295-8.
12. Wu AHB. Standardization of assays for clinically important enzymes that have high biologic variation: what is all the fuss about? [Editorial]. *Clin Chem Lab Med* 2010, 48:299-300.
13. Wu AHB. How much of a change in natriuretic peptides does one need to be clinically important and is that the same as biological variation. *Am Coll Cardiol Cardiac Markers*.

- [http://biomarkers.cardiosource.org/Ask-the-Expert/2010/09/How-Much-of-a-Change-in-Natriuretic-Peptides-Does-One-Need-to-be-Clinically-Important.aspx?w\\_nav=Search&WT.oss=biological%20variation&WT.oss\\_r=13&](http://biomarkers.cardiosource.org/Ask-the-Expert/2010/09/How-Much-of-a-Change-in-Natriuretic-Peptides-Does-One-Need-to-be-Clinically-Important.aspx?w_nav=Search&WT.oss=biological%20variation&WT.oss_r=13&)
14. Wong SH, Happy C, Blinka D, Gock S, Jentzen JM, Donald JM, Coleman H, Jortani SA, Lucire Y, Morris-Kukoski C, Neuman M, Sander TL, Wagner MA, Wynn JR, Wu AHB, Yeo J. From personalized medicine to personalized justice – assembling the framework with pharmacogenomics and assessing its applicability to the justice system. *Pharmacogen* 2010;11:731-7.
  15. Wu AHB. Biological variation for natriuretic peptides. Cardiac Biomarkers “Ask the expert” *Am Coll Cardiol*, [www.cardiosource.org/biomarkers](http://www.cardiosource.org/biomarkers); 2010.
  16. Rifai N, Wu A, Brugnara C, Delvin E, Lamb EJ, Ness PM, Wick MR. Full-disclosure in industry-sponsored laboratory medicine research studies: Statement by the consortium of laboratory medicine journal editors. [Editorial]. *Ann Clin Biochem* 2011;48:5-6, *Am J Hematol* 2011;86:244, *Clin Chem* 2011;57:359-60, *Clin Chim Acta* 2011;412:481-2, *Scan J Clin Lab Invest* 2011;71:177-8, *Clin Chem Lab Med* 2011;49:3-4, *Transfusion* 2010.
  17. Wu AHB. High-sensitivity troponin measurements and use of the 99<sup>th</sup> percentile cutoff: are they appropriate for the ICU? *Chest Phys* 2009;4(10):20-1.
  18. Plebani M, Wu AHB. Circulating macrocomplexes: old wine in new bottles? *Clin Chem Lab Med* 2011;49:759-60.
  19. Sidiropoulos N, Wu AHB. Clinical trials for pharmacogenomics testing for warfarin dosing: relevance to general community practices. *Genetics Med* 2011;13:505-8.
  20. Wu AHB, Lynch K. Point: Emergent confirmation still not needed for ED drug screening? NACB LMPG Guideline revisited. *Clin Foren Tox News* June, 2010: 1-6,
  21. Jaffe AS, Wu AHB. Troponin release. Reversible or irreversible injury? Should we care? [opinion] *Clin Chem* 2012, 58:148-50.
  22. Scott MG, Smith BR, Wu AH, Young IS, Plebani M, Chiu RWK. How well are we training the next generation of clinical pathologists and clinical laboratory directors? A global perspective. *Clin Chem* 2012;58:491-495.
  23. Wu AHB, Shin J. R-warfarin pharmacokinetics: is this another source of warfarin dose variability? *Person Med* 2011, 8:611-2.
  24. Wu AHB, Shin J. MDR1 polymorphism and warfarin resistance detection: is this the missing link? *Person Med* 2011, 8:612-3.
  25. Rifai N, Annesley TM, Berg JP, Brugnara C, Delvin E, Lamb EJ, Ness PM, Plebani M, Wick MR, Wu AH, Delange J. Appeal to medical journal editors: the need for a full description of laboratory methods and specimen handling in clinical study reports. *Clin Chem* 2012, 58:483-485, *Scan J Clin lab Invest* 2012;72:89-91, *Ann Clin Biochem* 2012 49:105-7, *Clin Chem Lab Med* 2012;50:411-3, *Am J Hematol* 2012;87:347-8, *Ann Clin Biochem* 2012;49:105-7, *Clin Chim Acta* 2012;413:653-5, *Transfusion* 2012;52:e15-6, *Clin Biochem* 2012;45:185-6.
  26. Wu AHB. Review of: Medical toxicology of drug abuse: synthetic chemicals and psychoactive plants. *J Foren Sci* 2012;57:1682.
  27. Wu AHB. Expert opinions on high sensitive Troponin. *Chin J Lab Med* 2012, accepted.

28. Wu AHB. Soluble ST2 in heart disease. Bliki, biomarkerbliki.org: 2012. <http://www.biomarkerbliki.org/bliki-completed-chapters-st2-overview.html>
29. Wu AHB. Cardiac troponins T and I for acute coronary syndromes. Bliki, biomarkerbliki.org: 2013. <http://www.biomarkerbliki.org/bliki-completed-chapters-troponin-i-and-t-overview.html>
30. Wu AHB, Bolger AF, Hollander JE. Growing pains with the use of high-sensitivity cardiac troponin assays. *J Am Coll Cardiol* 2013;62:1250-1
31. Wu AHB. Decision Support in Medicine on Laboratory Medicine. *Heart Failure*. 2013, <https://www.decisionsupportinmedicine.com/DSM/a/articles/33/H/3594>.
32. Wu AHB. Pharmacogenomic testing. Are you or your patients ready? *San Fran Med* 2013;86(9):19-20.
33. Wu AHB. The use of biological variation for the interpretation of cardiac biomarkers in the acute setting. *Am Coll Cardiol Biomarkers Clin Community*, Nov 2013. <http://www.acc.org/latest-in-cardiology/articles/2014/07/18/14/53/biological-variation-for-the-interpretation-of-cardiac-biomarkers-in-the-acute-setting>.
34. Wu AHB, Superko HR. The pharmacogenomics of warfarin from the COAG and EU-PACT: where do we go from here? *Person Med* 2014;11:247-9.
35. Wu AHB. Promoting clinical lab science. *Advance* 2014;23(5):10.
36. Wu AHB. Folate testing: time to retire your VCR. *JAMA Internal Medicine*, 2014, Published online August 11, 2014. doi:10.1001/jamainternmed.2014.3272
37. Wu AHB, Khalili M. The birth and potential death of IL28b genotyping for hepatitis C therapy. *Person Med* 2015;12:55-7
38. Apple FS, Hollander J, Wu AHB, Jaffe A. Improving the 510(k) process for cardiac troponin assays: in search for common ground. *Clin Chem* 2014;60:1273-5.
39. Wu AHB, Hale K. Predicting mortality after elective open heart surgery using MR-proADM: is it time to scalp APACHE IV? *Crit Care Med* 2014, in press.
40. Wu AHB. Pharmacogenomic testing and response to warfarin *Lancet* 2015, March 2015.
41. Wu AHB, Christenson RH. The Standards for Reporting Diagnostic accuracy studies 2015 update: is there a missing link to the triumvirate? *Ann Transl Med* 2016, 2016 Feb;4(3):44. doi: 10.3978/j.issn.2305-5839.2015.12.41.
42. Wu AHB. High-sensitivity cardiac troponin testing for primary care: analytical assay considerations required before widespread implementation. *Ann Transl Med* 2016,doi: 10.21037/atm.2016.06.28.
43. Wu AHB. Personalized justice: investigation of genotyping for wrongful death investigations. *Person Med* 2017,14:9-12.
44. Wu AHB. Pharmacogenomics for warfarin: too little too late? *Person Med* 2018;15(2):71-3.
45. Wu AHB, Anand I. The biological variation of proenkephalin. *Clin Chem Lab Med* 2018;<https://doi.org/10.1515/cclm-2018-0876>.
46. Wu AHB. AACC Academy's pain management LMPG: verification of drug dosing with quantitative urine drug testing? *J Appl Lab Med* 2018;2(4):475-7.
47. Wu AHB. The influence of pharmacogenomics on the protective effect of light to moderate alcohol use *Person Med* 2018;15(3):149-51.

48. Wu AHB. Promoting the value of precision medicine to the public: the power of story telling. *Exp Review Prec Med Drug Dev* 2018 DOI: 10.1080/23808993.2018.1506255

#### **BOOK CHAPTERS:**

1. Wu AHB. Ionized Calcium in Acute Care Medicine: Focus on liver transplantation. In *Ionized Calcium: Its determination and clinical usefulness*. Moran, RF, ed, 1987:36-43.
2. Wu AHB: Liver cancer. In: *Textbook of Clinical Lab Science*, Davis BG, Bishop ML, Mass D, eds., Lippincott, Philadelphia, 1988. Chapter 34, pp. 381-90.
3. Wu AHB, Sell S. Markers for hepatic carcinoma. In: *Immunodiagnosis of Cancer*, 2nd ed., Herberman RB, Mercer DW, eds., Dekker, New York, 1990:403-22.
4. Wu AHB. Enzymes in cardiovascular and skeletal muscular diseases. In: *Clinical Chemistry*, 3rd ed. Wu AHB, Chan KM, Lott JA, Hursting M. Health and Education Resources, Bethesda, MD, 1991:47-54.
5. Onigbinde TA, Wu AHB. Analytical techniques and instrumentation. In: *Clinical Chemistry, Principles, Procedures, and Correlation*, 2nd ed. Bishop ML, Duben-Engelkirk JL, Fody EP, eds., Lippincott, Philadelphia, 1991:103-32. 3rd edition: Laios I, Wu AHB, 1995:97-126, 4th edition. 6<sup>th</sup> ed., Drees J, Wu AHB, 2010;130-165. 7<sup>th</sup> ed. Petrie M.
6. Wu AHB. Renal Function. 2nd ed. Bishop ML, Duben-Engelkirk JL, Fody EP, eds., Lippincott, Philadelphia:1991:453-71. 3rd edition: Elie-Carlledge S, Wu AHB, 1996:359-80. 4th ed: Skarzynski C, Wu AHB. 6<sup>th</sup> ed., 7<sup>th</sup> ed Lynch K, Wu AHB, 2010;557-577.
7. Wu AHB. Requirements and considerations for clinical laboratory capabilities. In: *Proceedings of the Space Station Freedom Clinical Experts Seminar*, NASA Conference Pub. 10069, Houston, 1991:59-61.
8. Wu AHB. Chapter 11. Diagnostic Enzymology. In: *Clinical Laboratory Medicine*, McClatchey KM, ed., 1<sup>st</sup> ed., Lippincott Williams & Wilkins, Baltimore, MD, 1993:259-86. 2<sup>nd</sup> ed., 2002: 281-305.
9. Wu AHB. Myocardial Infarction. In: *Professional Practice in Clinical Chemistry: A Review*, D.R. Dufour, ed., American Association for Clinical Chemistry, Washington, DC, 1993: 117-136, 1995: 109-130, 1997: 303-324.
10. Wu AHB. Pancreas. In: *Professional Practice in Clinical Chemistry: A Review*, D.R. Dufour, ed., American Association for Clinical Chemistry, Washington, DC, 1993:137-152, 1995:131-148, 1997: 325-346.
11. Moore R, Luczyk K, Wu AHB. Workstation optimization. In: *Handbook of Clinical Laboratory Automation, Robotics and Optimization*, Kost GJ, Welsh J, Wiley, 1996:497-514.
12. Wu AHB. Immunoassays for drugs of abuse. In: *Analysis for Drugs of Abuse: Instrumental Methods & Techniques*, Ryan TW, ed., 1996.
13. Wu AHB. Cardiac markers for coronary artery diseases: need for random access testing. *Proceedings of the 5th Technicon Immuno 1 International Symposium*, Paris, Chase Medical Comm., Wilton, CT, 1996:65-9.



14. Tsongalis GJ, Rezuke WN, Wu AHB. An epidemiological study to evaluate the incidence of activated protein C resistance in the general population using a PCR-mediated restriction fragment length polymorphism assay: implications for the critical care patient. In: *Advances in Critical Care Testing*. List WF, Muller MM, McQueen MJ, eds., Springer, Berlin: 1996;211-22.
15. McKay CA, Wu AHB. Diagnostic modalities for the toxicology patient. In: *Emergency Medicine: The Core Curriculum*. Aghababian ed., Lippincott-Raven, New York, 1998;984-992.
16. Wu AHB. Introduction to coronary artery disease and cardiac markers. In: *Cardiac Markers*. Wu AHB ed., Humana Press, Totowa, NJ:1998:3-20.
17. Giri S, Waters DD, Wu AHB. Pathophysiology of acute coronary syndromes. In: *Cardiac Markers*. Wu AHB ed., Humana Press, Totowa, NJ:1998:21-44.
18. Wu AHB. Creatine kinase, isoenzymes, and variants. In: *Cardiac Markers*. Wu AHB ed., Humana Press, Totowa, NJ:1998:113-26.
19. Wu AHB. CK-MB activity assays. In: *Cardiac Markers*. Wu AHB ed., Humana Press, Totowa, NJ:1998:127-42.
20. Wu AHB. New biochemical markers for heart disease. In: *Cardiac Markers*. Wu AHB ed., Humana Press, Totowa, NJ:1998:218-94.
21. Wu AHB. Disease reflex algorithms for acute and long-term management of cardiac patients. *Proceedings of the 2nd and 3rd International Bayer Diagnostics Laboratory Testing Symposium*, New York City NY and Vienna Austria, Chase Medical Comm., Wilton, CT, 1998:38-40 and 38-41.
22. Wu AHB. Role of serum biochemical markers in clinical trials. In: *Myocardial Damage: Early Detection by Novel Biochemical Markers*. Kaski JC, Holt DW, Kluwer Publishers, 1998:189-200.
23. Wu AHB. Point-of-care testing and the patient with chest pain. In: *Point-of-care testing*. Price CP, Hicks J, ed., Am Assoc Clin Chem, Washington, DC: 1999:426-44.
24. Wu AHB, French D. Cardiac markers. In: *The Immunoassay Handbook*, Wild D, 2<sup>nd</sup> ed., Nature Publishing, London, UK:2001: 612-34. 3<sup>rd</sup> ed., 2005:649-663. 4<sup>th</sup> ed., 2013,:817-32.
25. Wu AHB. Cardiac markers. In: *Encyclopedia of Molecular Medicine*. Creighton TE, ed. John Wiley & Sons, New York, NY;2001:
26. Wu AHB. Cardiac markers. In: *Clinical Chemistry: Laboratory Management and Clinical Correlations*. Lewandrowski, ed., Lippincott Williams & Wilkins, New York, 2002:671-88.
27. Yeo KTJ, Quinn-Hall KS, Bateman SW, Fischer GA, Wieczorek S, Wu AHB. The functional sensitivity of cardiac troponin assays and its implications for risk-stratification for patients with acute coronary syndromes. In: *Markers in Cardiology*. Adams JE, Jaffe AS, Apple FS, Wu AHB, eds. AHA Monograph, Armonk, NY, 2001:23-30.
27. Apple FS, Adams JE, Wu AHB, Jaffe AS. Report on a survey of analytical and clinical characteristics of commercial cardiac troponin assays. In: *Markers in Cardiology*. Adams JE, Jaffe AS, Apple FS, Wu AHB, eds. AHA Monograph, Armonk, NY, 2001:31-4.

28. Wu AHB. Urine adulteration prior to testing for drugs of abuse. In: *The Clinical Toxicology Laboratory. Contemporary Practice of Poisoning Evaluation*. Shaw LM, Kwong TC, eds., AACC Press, 2001: 157-72.
29. Wu AHB. Point-of-care testing for drugs of abuse. In: *The Clinical Toxicology Laboratory. Contemporary Practice of Poisoning Evaluation*. Shaw LM, Kwong TC, ed., AACC Press, 2001: 145-56.
30. Wu AHB. Analytical issues affecting the clinical performance of cardiac troponin assays. In: *Markers in Cardiology*. Adams JE, Jaffe AS, Apple FS, Wu AHB, eds. AHA Monograph, Armonk, NY, 2001:1-12.
31. Wu AHB. Onsite Tests for Therapeutic Drugs. In: *Onsite Drug Testing*. Jenkins A, Goldberger B, ed. Humana Press, Totowa, NJ:2002:11-24.
32. Wu AHB. Point-of-care drug testing. In: *Point-of-care testing: principles, management, and clinical practice*. Kost GJ, ed., Lippincott Williams & Wilkins, Baltimore, 2002:253-66.
33. Wu AHB. The rationale for point-of-care testing (POCT) for drugs of abuse and ethyl alcohol. In: *Point of care testing: performance improvement and evidence-based outcomes*. Nichols JH, ed., Marcel Dekker, Inc., New York, NY, 2003:439-53.
34. Wu AHB. Polymorphisms related to acute coronary syndromes and heart failure. Potential targets for pharmacogenomics. In: *Cardiac Markers, 2<sup>nd</sup> ed.*, Wu AHB, ed., Humana Press, Totowa, NJ: 2003:437-58.
35. Wu AHB, Mockel M, Danne O, Fagan G, Keffer J. Ischemia-modified albumin, free fatty acids, whole blood choline, B-type natriuretic peptide, glycogen phosphorylase BB, and cardiac troponin. In: *Cardiac Markers, 2<sup>nd</sup> ed.*, Wu AHB, ed., Humana Press, Totowa, NJ: 2003:259-77.
36. Wu AHB. Analytical issues and the evolution of cutoff concentrations for cardiac markers. In: *Cardiac Markers, 2<sup>nd</sup> ed.*, Wu AHB, ed., Humana Press, Totowa, NJ: 2003:231-41.
37. Wu AHB. Molecular pathogenesis of cardiovascular disease. In: *Molecular Diagnostics For the Clinical Laboratorian, 2<sup>nd</sup> ed.*, Coleman WB, Tsongalis GJ, eds., Humana Press, Totowa, NJ: 2005:295-308.
38. Storrow A, B, Apple FS, Wu AHB, Jesse R, Francis G, Christenson RH. Use of cardiac biomarkers for acute coronary syndromes. In: *National Academy of Clinical Biochemistry Evidence-based practice for point-of-care testing*. AACC Press, Washington DC, 2006: Chapter 3.
39. Wu AHB. Analytical issues for clinical use of cardiac troponin. In: *Cardiovascular Biomarkers. Pathophysiology and Disease Management*. Morrow DA, ed., Human Press, Totowa, NJ: 2006:27-40.
40. Wu AHB. Myocardial injury: pathophysiology of coronary artery disease. In: *“Contemporary Practice in Clinical Chemistry”* Clarke W, Dufour DR, eds., 2006:261-8, 2016:357-76.
41. Wu AHB. Normal anatomy and physiology of the pancreas. In: *“Contemporary Practice in Clinical Chemistry”* Clarke W, Dufour DR, eds., AACC Press, Washington DC, 2006:281-8.

42. Wu AHB. Plasma BNP/NT-proBNP assays: what do they target and what else might they recognize? In: "Heart Failure Clinics. Natriuretic peptides. Mills RM, Tang WHW, Burnett JC, Jr., Eds., Elsevier Inc., Philadelphia. 2006:291-8.
43. Storrow AB, Apple FS, Wu AHB, Jesse A, Francis G, Christenson RH. Cardiac biomarkers for acute coronary syndromes. In: National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines, Evidence-Based Practice for Point-of-Care Testing. Nichols JH, ed., Chapter 3, NACB, 2006: pp. 13-20.
44. Wu AHB. Standards for reporting of diagnostic accuracy (STARD): relevance to clinical laboratory studies. In: "Evidence-based laboratory medicine. From principles to outcomes." 2<sup>nd</sup> ed., Price CP, Christenson RH, eds. AACC Press, Washington DC, 2007;165-187.
45. Wu AHB. Basics of natriuretic peptides: practical aspects of assays, potential analytic confounders, and clinical interpretation. In: "Markers in Cardiology: A Contemporary Case-Oriented Approach." Adams JE, Jaffe A, Apple FS, eds. 2007, pp. 128-133.
46. Wu AHB. Myoglobin. In: Clinical Chemistry. Theory, analysis, correlation. 5<sup>th</sup> ed., Kaplan LA, Pesce A, eds., Mosby, St. Louis, 2008.
47. Wu AHB. B-type natriuretic peptide, NT-proBNP, and proBNP. In: Clinical Chemistry. Theory, analysis, correlation. 5<sup>th</sup> ed., Kaplan LA, Pesce A, eds., Mosby, St. Louis, 2008.
48. Wu AHB. Assessment of myocardial injury. In: Principles of Clinical Laboratory Medicine. Ansari MG, Wians FH, Hashim IA, eds. Am Soc Clin Pathol Press, Chicago, IL, 2009.
49. Wu AHB. Troponins: Laboratory Issues. In: Cardiac Biomarkers in Modern Medicine: Practical Knowledge for the Clinician. Januzzi J, ed., Jones and Bartlett, Boston, 2010:47-62.
50. Wu AHB. Myoglobin. In: Methods in Clinical Chemistry, Kaplan and Pesce's Clinical Chemistry: Theory, Analysis, Correlation. 5<sup>th</sup> ed. Hickman PE, Koerbin G, eds., Pesce Kaplan Publishers, 2009:891-6.
51. Yeo KTJ, Babic N, Wu AHB. Issues in translation of pharmacogenomics into clinical practice. In: Wu AHB, Yeo YTJ, eds. Pharmacogenomic testing in current clinical practice. Implementation in the clinical laboratory. Human Press, Totowa NJ, 2011:3-14.
52. Wong SHY, Happy C, Blinka D, Goch S, Jensen JM, Donald JM, Coleman H, Jortani SA, Lurie Y, Morris-Kukoski CL, Newman MG, Orsulak PJ, Sander , Wagner MA, Wynn JR, Wu AHB, YUeo KTJ. From personalized medicine to personalized justice: the promises of translational pharmacogenomics in the justice system. In: Wu AHB, Yeo YTJ, eds. Pharmacogenomic testing in current clinical practice. Implementation in the clinical laboratory. Human Press, Totowa NJ, 2011:47-58.
53. Wu AHB. Economics of pharmacogenomics testing in clinical practice. In: Wu AHB, Yeo YTJ, eds. Pharmacogenomic testing in current clinical practice. Implementation in the clinical laboratory. Human Press, Totowa NJ, 2011:35-46.
54. Wu AHB. Biomarkers for coronary artery disease and heart failure. In: "Contemporary Practice in Clinical Chemistry" 2<sup>nd</sup> ed., Clarke W, eds., 2011:299-310.

55. Wu AHB, Herr A. Need for point-of-care testing devices for cardiac troponin in patients with acute coronary syndromes. In: Biomedical Engineering Handbook, 4<sup>th</sup> ed., in preparation.
56. Wu AHB. Laboratory perspective on biomarkers for acute coronary syndromes. In: Maisel A, ed., Cardiac biomarkers in clinical practice: present and future applications. Jaypee Brothers, Delhi, India, 2011:62-73.
57. Wu ABH. Pharmacogenomic testing and the future of hospital toxicology. In: Clinical Toxicology Testing. A guide for laboratory professionals. Magnani B, Bissell MG, Kwong TC, Wu AHB, eds., CAP Press, 2012: 241-250.
58. Tchu S, Lynch K, Wu AHB. Therapeutic Drug Monitoring of Tamoxifen using LC-MS/MS. In: Methods in Molecular Biology - LC-MS in Drug Analysis, Langman LJ, Snozek CLH. eds., Springer, New York NY: 2012;902:211-22.
59. Wu AHB. Pharmacogenomics: tailoring treatment based on genotype. In: "Molecular Genetics and Personalized Medicine", Best and Swensen, eds., Springer, 2012:37-50.
60. Wu AHB, Lynch K. Therapeutic drug monitoring to support clinical pharmacogenomics. In: Xu QA, ed. Liquid chromatography-mass spectrometry in clinical pharmacology. Springer, 2011. Submitted.
62. Wu AHB. Medical Toxicology of Drug Abuse: Synthetic Chemicals and Psychoactive Plants, book review. J Foren Sci 2012, in press.
63. Wu AHB. Immunoassays. Bishop ML, Fody EP, Schoeff LE eds., Lippincott, Philadelphia, 7<sup>th</sup> ed, 2013: 160-178.
64. Wu AHB. Creatine kinase, isoenzymes and isoforms. In: Diagnostic Enzymology, 2<sup>nd</sup> ed., Kazmierczak S, Azzazy H, ed., De Gruyter, Germany; 2014: 105-120.
65. French D, Wu AHB. Patient dependent variable. In: Managing the Preanalytical Process to Ensure Timely and Accurate Patient Results, Stankovic, Green S, Chance, ed., 2015, in preparation.
66. Wu AHB. Natriuretic peptides: basic analytic considerations. In: Maisel A, Jaffe A. Cardiac Biomarkers: Case Studies and Clinical Correlations, Springer, 2015, in preparation.
67. Ruano G, Seip R, Windemuth A, Wu AHB, Thompson PD. Laboratory medicine in the clinical decision support for treatment of hypercholesterolemia: pharmacogenetics of statins. In: Reynolds KK, Valdes R Jr., Clin Lab Med 2016;36:473-492.
68. Wu AHB. Utilization management in clinical chemistry. In: Lewandrowski K, Sluss PM. Utilization Management in the clinical laboratory and other ancillary services. Springer, Switzerland: 2017; 89-94.
69. Wu AHB. Immunoassay. In: eLS. John Wiley & Sons, Ltd: Chichester. DOI: 10.1002/9780470015902.a0001135.pub2
70. Smith A, Wu AHB. Analytical and clinical concordance of free light chain assays. Clin Biochem 2018, submitted.
71. Kwong T, Wu ABH. Laboratory based screening assays. In: Clinical Toxicology Testing. A guide for laboratory professionals, 2<sup>nd</sup> ed. Magnani B, Bissell MG, Kwong TC, Wu AHB, eds., CAP Press, 2019: in press.

72. Wu ABH, McMillin G. Pharmacogenomic testing. In: Clinical Toxicology Testing. A guide for laboratory professionals, 2<sup>nd</sup> ed. Magnani B, Bissell MG, Kwong TC, Wu AHB, eds., CAP Press, 2019: in press.

#### **BOOKS AND MONOGRAPHS:**

1. Brewster MA, Turley CP, Wu AHB. Clinical Chemistry Self-Assessment, 2nd ed., AACC Press, Washington, DC, 1989.
2. Wu AHB, Chan KM, Hursting MJ, Lott JA, Spillman T, Wheaton RN. Clinical Chemistry, 2nd ed., Health Education Resources, Bethesda, MD, 1991.
3. Wu AHB. Cardiac Markers. Humana Press Inc., Totowa, NJ, 1998.
4. Wu AHB, Moore R, Tsongalis G, Burnett RW. Clinical Chemistry Self-Assessment, 3rd ed., AACC Press, Washington, DC, 2000.
5. Wu AHB, Apple FS, Warshaw MM. Recommendations for the use of cardiac markers in coronary artery diseases. National Academy of Clinical Biochemistry, Washington, DC:2000.
6. Adams JE, Jaffe AS, Apple FS, Wu AHB, eds. Markers in Cardiology. AHA Monograph, Armonk, NY, 2001.
7. Wu AHB. Cardiac Markers, 2<sup>nd</sup> ed. Humana Press Inc., Totowa, NJ, 2003.
8. Adams J, Apple F, Christenson R, Kahn S, Robberts W, Sacks D, Wu AHB. Laboratory testing for cardiac disease:options and answers. AACC, Washington, DC, 2003.
9. Wu AHB, editor. Tietz Clinical Guide to Laboratory Tests, 4<sup>th</sup> ed., Elsevier Science, New York, 2006.
10. Wu AHB. Clinical Chemistry Self-Assessment, Vol. 2, AACC Press, Washington, DC, 2008.
11. Wu AHB, Yeo KTJ. Pharmacogenomic testing in current clinical practice. Implementation in the clinical laboratory. Humana Press, Totowa, NJ, 2011.
12. Olson K, Anderson IB, Benowitz NL, Blanc PD, Clark RF, Kearney TE, Wu AHB, eds. Poisonings and drug overdose. Lange, 6<sup>th</sup> ed., 2011.
13. Magnani B, Bissel MG, Kwong TC, Wu AHB, eds. Clinical toxicology testing. A guide for laboratory professionals. CAP Press, 2012.
14. Wu AHB. Toxicology! Because what you don't know can kill you. Amazon Press, 2014.
15. Wu AHB. The hidden assassin. When clinical lab tests go awry. Amazon Press, 2014.
16. Wu AHB. Microbiology! Because what you don't know will kill you. Amazon Press, 2014.
17. Wu AHB. Performance enhancing drugs and adulterants: The hidden assassin II. Amazon Press, 2015.
18. Wu AHB. Mind Portal. Amazon Press, 2016.

Updated: 1/2018